Tissue engineering a pancreatic substitute based on recombinant intestinal endocrine cells by Bara, Heather Lynn
  
TISSUE ENGINEERING A PANCREATIC SUBSTITUTE BASED ON 



























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 













TISSUE ENGINEERING A PANCREATIC SUBSTITUTE BASED ON 


























Approved by:   
   
Dr. Athanassios Sambanis, Advisor 
School of Chemical & Biomolecular 
Engineering 
Georgia Institute of Technology 
 Dr. Joseph Le Doux 
School of Biomedical Engineering 
Georgia Institute of Technology 
   
Dr. Ravi Bellamkonda 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Peter Thulé 
School of Medicine, Endocrinology 
Emory University 
   
Dr. Andrés García 
School of Mechanical Engineering 
Georgia Institute of Technology 
  
   
  Date Approved:  October 31, 2008 
 iii 
ACKNOWLEDGEMENTS 
First and foremost, I would like to express my sincere gratitude to Dr. 
Athanassios Sambanis, who has been an incredible advisor and mentor.  His impact on 
the development of my professional career has been immeasurable.  I would also like to 
thank the members of my committee, Drs Bellamkonda, García, Le Doux, and Thulé, for 
their contributions and commitment to this project.  I am also grateful to the universities 
of Georgia Tech and Emory for allowing me to study in such an amazing academic 
environment.  The BME department, the IBB, and GTEC provided me with countless 
opportunities to conduct and present my scientific work, and to grow professionally in 
other areas, such as teaching and mentoring.  For the development of my teaching skills, I 
am especially indebted the Gandy/Diaz teaching fellowship and my mentor, Dr. Lena 
Ting.  Her excellence in teaching has given me much to aspire to. 
I would also like to extend sincere thanks to all of the Sambanis lab members, 
including Shing-Yi Cheng, Tony Tang, Cheryl Stabler, Jeff Gross, Neil Mukherjee, 
Angela Gulino, Hajira Ahmad, Fernie Goh, Alison Stucky, and Saif Al-Mamari.  This 
was a truly incredible group of individuals to work with and have been so helpful in my 
research.  Tony Tang was my mentor on the L-cell project and set an incredible example 
for me from day 1.  Cheryl Stabler, even after leaving the lab, she was incredibly helpful 
in answering any questions I had about working with mice.  Jeff Gross, Neil Mukherjee, 
and Angie Gulino were amazing friends and sounding boards that helped me to work out 
issues with my project and encouraged me every step of the way.  Alison Stucky was so 
understanding and giving of her time in helping me with my in vivo studies.  She was my 
anesthesiologist and provided pre- and post-operative care to the mice.  I don’t know 
what I would have done without her.  Danielle Henkel came to us briefly to conduct some 
 iv 
undergraduate summer research and was very helpful in allowing me to advance the 
project into Aim 2, while I focused on other issues still present in the first aim. 
Additionally, I am incredibly grateful to the agencies and corporations that 
provided the funding for this project.  Primary support was provided by the National 
Institutes of Health (NIH) R01DK076801 and by the ERC program of the National 
Science Foundation (NSF), the Georgia Tech and Emory Center (GTEC) for the 
Engineering of Living Tissues, under award number EEC-9731643.  Funding was also 
provided by Johnson & Johnson Healthcare Innovation Program, the GAANN 
Fellowship, and the Gandy/Diaz Teaching Fellowship.  This work was also made 
possible through the generous donations of materials: the B10 human insulin gene by 
Genentech, GLUTag cells by Drs. Brubaker and Drucker (University of Toronto, 
Ontario, Canada), STC-1 cells by Dr Hanahan (University of California), and small 
intestinal submucosa by Cook Biotech. 
Finally I would not be the person I am today were it not for the loving support of 
my family.  My parents Dave and Cheryl Virginia have encouraged me and pushed me to 
excel through every stage of my academic development and I am forever grateful to 
them.  I am also very thankful to my in-laws Bob and Connie Bara for welcoming me 
into the family and providing me with a loving home away from home right here in 
Atlanta which has been a source of comfort over the last four and a half years.  I would 
especially like to thank my husband George, especially for his unrelenting love, 
especially during the last semester, when I probably did not deserve it. 
 v 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES x 
LIST OF FIGURES xi 
LIST OF ABBREVIATIONS xiv 
SUMMARY xvi 
CHAPTER 
1 INTRODUCTION 1 
2 BACKGROUND 7 
2.1 Diabetes 7 
2.2 Insulin Therapy 7 
2.3 Current and Future Cell-Based Therapies 9 
2.3.1 Islet Transplantation 10 
2.3.1.1 Allogeneic Islet Transplantation  10 
2.3.1.2 Xenogeneic Islet Transplantation 12 
2.3.2 Differentiation of Stem Cells into β-cells 13 
2.3.2.1 Differentiation of Embryonic Stem Cells into β-cells 15 
2.3.2.2 Differentiation of Adult Stem Cells into β-cells 16 
2.3.3 Transdifferentiation and Metaplasia 17 
2.3.4 Genetic Engineering of Autologous Non-β-cells 18 
2.3.5 Enteroendocrine Cells for the Treatment of Diabetes 20 
2.3.6 Autoimmunity in Type 1 Diabetes 23 
2.4 Studying L-cells In Vitro 24 
 vi 
2.5 Tissue Engineered Pancreatic Substitutes 26 
2.6 Animal Models of Insulin-Dependent Diabetes 28 
3 INSULIN-SECRETING L-CELLS FOR THE TREATMENT OF INSULIN-
DEPENDENT DIABETES 30 
3.1 Introduction 30 
3.2 Materials and Methods 33 
3.2.1 Cell Culture 33 
3.2.2 Antibody Staining and Microscopy 33 
3.2.3 Transfection and Selection of Stable Clone 34 
3.2.4 Induced Secretion Tests 35 
3.2.5 Assays 36 
3.3 Results 36 
3.3.1 PC1/3 and PC2 Expression in GLUTag Cells 36 
3.3.2 Generation of a Stable Insulin-Expressing GLUTag Clone 36 
3.3.3 Induced Secretion of Insulin and GLP-1 from GLUTag-INS Cells 37 
3.3.4 Secretion Profile of Insulin from GLUTag-INS Cells 39 
3.3.5 Proinsulin Conversion in GLUTag-INS Cells 40 
3.4 Discussion 41 
3.4.1 PC1/3 and PC2 Expression in GLUTag Cells 41 
3.4.2 Generation of a Stable Insulin-Expressing GLUTag Clone 42 
3.4.3 Induced Secretion of Insulin and GLP-1 from GLUTag-INS Cells 43 
3.4.4 Detailed Secretion Profile of Insulin from GLUTag-INS Cells 45 
3.4.5 Proinsulin Conversion in GLUTag-INS Cells 45 
 
 vii 
4 DEVELOPMENT AND IN VITRO CHARACTERIZATION OF A TISSUE 
ENGINEERED PANCREATIC SUBSTITUTE BASED ON RECOMBINANT 
INTESTINAL ENDOCRINE L-CELLS 46 
4.1 Introduction 47 
4.2 Materials and Methods 49 
4.2.1 Cell Culture 49 
4.2.2 Construct Design and Fabrication 49 
4.2.3 Viability Assessment of GLUTag-INS Cells Cultured on SIS 51 
4.2.4 TEPS Culture and In Vitro Evaluation 52 
4.2.5 Assays 52 
4.3 Results 53 
4.3.1 Viability and Total Cell Number over Time 53 
4.3.2 Glucose Consumption Rates 55 
4.3.3 Insulin Secretion Rates 56 
4.3.4 Induced Insulin Secretion 58 
4.4 Discussion 59 
5 IN VIVO EVALUATION OF TISSUE ENGINEERED PANCREATIC 
SUBSTITUTES BASED ON RECOMBINANT L-CELLS 64 
5.1 Introduction 64 
5.2 Materials and Methods 66 
5.2.1 Fabrication of TEPS 66 
5.2.2 Induction of Diabetes 67 
5.2.3 Implantation of Artificial Pancreases 67 
5.2.4 Monitoring Body Weight and Blood Glucose 68 
5.2.5 Plasma Insulin Levels 68 
5.2.6 Retrieval of Artificial Pancreases 69 
 viii 
5.2.7 Insulin Secretion from Implants 69 
5.2.8 Live/Dead Staining and Confocal Microscopy 69 
5.2.9 Immunohistochemistry of Constructs 69 
5.2.10 Liver Glycogen Storage 70 
5.3 Results 71 
5.3.1 Monitoring Body Weight and Blood Glucose 71 
5.3.1.1 Implantation of Constructs of Disk Geometry 71 
5.3.1.2 Implantation of Constructs of Bead Geometry 75 
5.3.2 Plasma Insulin Levels 78 
5.3.3 Insulin Secretion from Implants 79 
5.3.4 Construct Retrieval and Inspection 80 
5.3.5 Live/Dead Staining and Confocal Microscopy 81 
5.3.6 Immunohistochemistry of Constructs for Host Immune Response 81 
5.3.7 Insulin Immunohistochemistry of Constructs 85 
5.3.8 Liver Glycogen Storage 86 
5.4 Discussion 87 
6 CONCLUSIONS AND FUTURE DIRECTIONS 93 
6.1 Conclusions 93 
6.2 Future Directions 96 
6.2.1 Increasing Insulin Expression 96 
6.2.2 Increasing Cell Loading of TEPS 96 
6.2.3 Genetic Engineering of Primary L-cells 98 
APPENDIX A: ISOLATION OF PRIMARY L-CELLS 100 
A.1 Introduction 100 
A.2 Materials and Methods 100 
 ix 
A.2.1 Colonic Crypt Isolation 100 
A.2.2 Viability Assays 102 
A.3 Results 102 
A.4 Discussion 107 
APPENDIX B: TRANSFECTION AND TRANSDUCTION OF L-CELLS LINES       
 109 
B.1 Introduction 109 
B.2 Materials and Methods 109 
B.2.1 Transfection of Cell Lines 109 
B.2.2 Transduction of Cell Lines 110 
B.3 Results and Discussion 110 
B.3.1 Transfection of Cell Lines 110 
B.3.2 Transduction of Cell Lines 112 
APPENDIX C: L-CELL SPECIFIC GENE EXPRESSION 114 
C.1 Introduction 114 
C.2 Materials and Methods 115 
C.2.1 Proglucagon Promoter Description and Primer Design 115 
C.2.2 PCR Cloning of the Proglucagon Promoter 117 
C.2.3 Gene Construct Generation 118 
C.2.4 Transfection and Luciferase Expression Assay 120 




LIST OF TABLES 
Table 4.1: Tissue Engineered Pancreatic Substitutes Evaluated in this Study 50 
Table 4.2: Comparison of Insulin Secretion Rates of GLUTag-INS Cells on Tissue 
Culture Plastic and SIS 58 
Table 5.1: Experimental Groups Used in Each In Vivo Study 68 
Table 5.2: Insulin Secretion from Implants Pre-implantation and Post-explantation 79 




LIST OF FIGURES 
Page 
Figure 2.1:  The spectrum of cell-based therapies for the treatment of insulin-
dependent diabetes 9 
Figure 2.2:  Overall process of islet transplantation 10 
Figure 2.3:  The origin, isolation, and specialization of embryonic stem cells 14 
Figure 2.4:  Gastric emptying and release of incretin hormones after glucose 
ingestion in humans 20 
Figure 2.5:  Structure of a single colonic crypt 22 
Figure 3.1:  Elements of the plasmid used for generation of the stable GLUTag 
clone expressing human B10-mutated insulin 34 
Figure 3.2:  Scheme used for changes in culture medium during induced secretion 
tests 35 
Figure 3.3:  Confocal images of PC1/3 and PC2 immunofluorescence staining 36 
Figure 3.4:  Confocal images of insulin immunofluorescence staining 37 
Figure 3.5:  Insulin release during induced secretion tests 38 
Figure 3.6:  GLP-1 release during induced secretion tests 39 
Figure 3.7:  Time course of insulin secretion from GLUTag-INS cells 40 
Figure 3.8:  Proinsulin conversion of GLUTag-INS cells in basal and induction 
medium 41 
Figure 4.1:  Live/Dead staining of GLUTag-INS cells cultured on SIS for 7 days 53 
Figure 4.2:  Total cell number vs. time of three types of TEPS 54 
Figure 4.3:  Glucose consumption rate (GCR) of GLUTag-INS cells in three types 
of TEPS over time 56 
Figure 4.4:  Insulin secretion rate (ISR) of GLUTag-INS cells in three types of 
TEPS over time 57 
Figure 4.5:  Induced insulin secretion tests 59 
Figure 5.1:  Body weights of mice implanted with disk-shaped constructs 73 
 xii 
Figure 5.2:  Blood glucose levels in mice implanted with disk-shaped constructs 74 
Figure 5.3:  Body weights of mice implanted with microbead constructs 76 
Figure 5.4:  Blood glucose levels in mice implanted with microbead constructs 77 
Figure 5.5:  Blood plasma levels of murine and human insulin in mice implanted 
with disk-shaped constructs 78 
Figure 5.6:  Appearance of disk-shaped constructs post-explantation 80 
Figure 5.7:  Confocal images of Live/Dead stained SIS removed from implanted 
disk-shaped constructs 81 
Figure 5.8:  Macrophage staining of constructs using a CD68 antibody 83 
Figure 5.9:  Neutrophil staining of constructs using a NIMP-R14 antibody 84 
Figure 5.10:  Insulin staining of constructs using a monoclonal insulin antibody 85 
Figure 5.11:  Liver gycogen storage of mice implanted with disk-shaped constructs 86 
Figure A.1:  Overall scheme of the isolation process used to obtain primary murine 
colonic crypts 102 
Figure A.2:  Live/Dead stain of freshly isolated whole colonic tissue 103 
Figure A.3:  Representative image of isolated murine colonic crypts 103 
Figure A.4:  Live/Dead staining of a colonic crypt cell preparation three hours after 
isolation 104 
Figure A.5:  Viability time course for crypts isolated by the Matrisperse digestion 
solution and plated on Matrigel-coated wells 105 
Figure A.6:  Viability time course for crypts isolated by the collagenase and dispase 
digestion solution and plated on Matrigel-coated wells 106 
Figure A.7:  Viability time course for crypts isolated by the Matrisperse digestion 
solution and plated on collagen-coated wells 107 
Figure B.1:  GLUTag cells transfected with FugeneHD or Lipofectamine 111 
Figure B.2:  STC-1 cells transfected with FugeneHD or Lipofectamine 111 
Figure B.3:  NIH-3T3 cells transfected with FugeneHD or Lipofectamine 112 
Figure B.4:  STC-1 cells transduced with AdTrack 113 
 xiii 
Figure B.5:  GLUTag cells transduced with adG3Fur/AdCMV-GFP 113 
Figure C.1:  Sequence of the glucagon gene promoter region used for PCR cloning 115 
Figure C.2:  Schematic of the 5’ flanking enhancer and promoter elements of the 
proglucagon promoter from -50 bp to -350 bp 116 
Figure C.3:  Vector map of the pRLnull expression plasmid 118 
Figure C.4:  Cloning scheme to correct the mPGp placement in the pRLnull vector  120 
Figure C.5:  Sequence of the cloned vector containing the proglucagon promoter 121 
Figure C.6:  Proglucagon promoter expression in various cell lines normalized to 
null vector expression 122 
Figure C.7:  Proglucagon promoter expression in various cell lines normalized to 
CMV vector expression 122 
 xiv 
LIST OF ABBREVIATIONS 
 
B10  Histidine to Aspartic Acid Substitution  
at Position 10 of the B Chain of Insulin 
C57Bl6/J  C57 Black 6 Jackson Labs Strain of Mouse  
CMV  Cytomegalovirus 
CRE  cAMP Responsive Element 
DMEM  Dulbeco’s Modified Eagle Medium 
DNA  Deoxyribonucleic Acid 
EGFP  Enhanced Green Fluorescent Protein 
FRIC  Fetal Rat Intestinal Cells 
FBS  Fetal Bovine Serum 
GIP  Gastric Inhibitory Polypeptide 
GK  Glucokinase 
GLP-1  Glucagon-like Peptide-1 
GLUT2  Glucose Transporter 2 
HBSS  Hank’s Balanced Salt Solution 
IBMX  3-isobutyl-1-methylxanthine 
IDD  Insulin-Dependent Diabetes 
IgG  Immunoglobulin G 
MH  Meat Hydrolysate 
mPGp  Mouse Proglucagon Promoter 
NOD  Non-Obese Diabetic 
PBS  Phosphate Buffered Saline 
PC1/3  Prohormone Convertase 1/3 
 xv 
PC2  Prohormone Convertase 2 
PCR  Polymerase Chain Reaction 
RIA  Radioimmunoassay 
Rneo  Neomycin Resistance 
SIS  Small Intestinal Submucosa 
STZ  Streptozotocin 
SV40  Simian Virus 40 
TEPS  Tissue Engineered Pancreatic Substitute(s) 











Cell-based treatments for insulin-dependent diabetes (IDD) may provide more 
physiologic regulation of blood glucose levels than daily insulin injections, thereby 
reducing the occurrence of secondary complication associated with IDD.  An autologous 
cell source is especially attractive for regulatory and ethical reasons and for 
circumventing the need for immunosuppression, which is currently standard for islet 
transplantation.  Our approach focuses on using adult non-β-cells engineered for 
physiologic insulin secretion.  Specifically, we utilize enteroendocrine L-cells, which 
naturally exhibit regulated secretion of GLP-1 in response to physiologic stimuli, and 
upon genetic engineering, co-secrete insulin in a regulated manner.  The overall goal of 
this project is to develop a tissue engineered pancreatic substitute based on a recombinant 
enteroendocrine cell line and test the efficacy of the pancreatic substitute by implantation 
into diabetic mice.  The specific aims of this thesis were to (1) to modify murine L-cells 
for regulated insulin secretion and evaluate the insulin secretion properties of the 
recombinant cells; (2) to incorporate insulin-secreting L-cells into an implantable 
construct containing small intestinal submucosa (SIS) and to evaluate insulin secretion 
from the construct in vitro; and (3) to test the efficacy of the tissue engineered pancreatic 
substitute in vivo by implanting it intraperitoneally in mice made diabetic by 
streptozotocin.  Thus, this proposal takes a tissue engineered pancreatic substitute for 





Insulin-dependent diabetes is a chronic disease which increases the morbidity and 
reduces the life-expectancy of the nearly five million people affected by this disease in 
the United States alone, based on the most recent Figures provided by the CDC (National 
Diabetes Fact Sheet, CDC 2007).  Though insulin injections and infusions can manage 
the disease, exogenous insulin is not sufficient to prevent the onset of very serious 
secondary complications including heart and kidney disease, peripheral nerve damage, 
and blindness.  Cell-based therapies, such as allogeneic islet transplantation, which is 
currently clinically implemented at a small scale, provide better physiological blood 
glucose regulation less invasively than traditional insulin therapy, thereby potentially 
improving lifestyle and reducing the occurrence of secondary complications.  Though the 
improvement of lifestyle gained by becoming insulin-independent must be balanced with 
the side-effects of the immuno-suppressive regiment used to prevent rejection of the 
allograft, and long-term graft survival has not been widely achieved in order to assess 
whether there is indeed a reduction in the occurrence of secondary complications 
(Bertuzzi, Marzorati et al. 2006).  Another drawback of allogeneic islet transplantation is 
that it may not be applied to a large population because of severe limitations in human 
donor tissue. 
Other cell-based treatments of IDD include the use of encapsulated β-cell lines or 
xenogeneic islets; differentiation of adult or embryonic stem cells toward a β-cell ph 
enotype; and genetic engineering of non-β-cells toward the development of β-cell 
surrogates.  As with allogeneic islet transplantation, the use of cell lines and xenogeneic 
islets also carry the burden of recipient immunosuppresion in order to prevent their 
rejection.  The generation of insulin-secreting cells from embryonic stem cells is 
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hampered by the fact that pancreatic cells appear late during embryonic development. 
Thus, generation of insulin-secreting cells from embryonic stem cells would involve the 
sequential activation and deactivation of a considerable number of genes controlling first, 
the generation of endoderm lineage cells, the subsequent generation of the precursors of 
pancreatic cells, and finally differentiation to insulin-secreting cells (Docherty, Bernardo 
et al. 2007).  Adult stem cells, particularly those coming from the pancreas, seem to be 
easier to fully differentiate but are more difficult to proliferate (Soria, Bedoya et al. 
2005).  Furthermore, the transplantation of the newly derived β-cells would be subject to 
destruction by the autoimmunity that caused the onset of diabetes in the first place 
(Monti, Scirpoli et al. 2008) and allograft rejection for the case of β-cells derived from 
embryonic stem cells.   
The use of non-β-cells from the patients themselves relaxes the requirements of 
availability and immune acceptance, but is hindered by the need to reconstitute the 
complex regulatory system of insulin production and secretion inherent to the β-cell.  
Several potential cell sources have been investigated in attempts to producing β-cell 
surrogates, including endocrine pituitary cells (Hughes, Quaade et al. 1993; Motoyoshi, 
Shirotani et al. 1998), muscle cells (Yin and Tang 2001), skin cells (Lei, Ogunade et al. 
2007), and liver cells (Huang, Thule et al. 1995; Thule, Liu et al. 2000; Thule and Liu 
2000; Olson, Paveglio et al. 2003).  Though great strides have been made in this area, 
each of these potentially autologous cell sources has its drawbacks. 
Recently, enteroendocrine cells (specialized endocrine cells of the gastrointestinal 
tract) have emerged on the scene as a promising cell source for engineering surrogate β-
cells.  The unique connection between their naturally secreted incretins and insulin 
secretion makes the engineering of enteroendocrine cells for regulated insulin secretion 
an appealing approach in terms of the dynamic release of insulin, as well as the 
compatibility of incretins and insulin in glycemic normalization.  A novel study by 
Anthony Cheung and colleagues in 2000  demonstrated that insulin produced and 
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secreted by genetically modified intestinal K cells of transgenic mice prevented those 
animals from becoming diabetic when injected with streptozotocin (Cheung, Dayanandan 
et al. 2000).  Similarly, transgenic mice which produced human insulin in gastric G cells, 
displayed a meal-regulated increase in the level of transgenic insulin and a corresponding 
decrease in blood glucose levels (Lu, Sternini et al. 2005).  These are important proof-of-
concept studies which showed that enteroendocrine cell-produced insulin can provide 
regulation of blood glucose levels.  Much work remains, however, in translating the 
results seen in transgenic mice to adult models of IDD.   
The most direct application suggested by these transgenic mice for treating IDD 
in an adult animal would be to genetically engineer the appropriate enteroendocrine cells 
in their natural environment, that is, in vivo gene therapy.  Besides significant difficulties 
inherent to delivering and stably expressing recombinant insulin in L-cells in vivo, a 
major challenge of in vivo gene therapy is in carefully titrating the treatment, so as not to 
overdose the patient with the transgene, as this might result in sustained over-production 
of insulin, an error that could be fatal.  Performing the necessary genetic modifications in 
a closely controlled manner outside of the body would greatly enhance safety.  A TEPS 
would not only provide the safety and quality control of in vitro gene therapy, but could 
additionally allow for retrieval of the construct and cells, if necessary, and for the non-
invasive monitoring of the implant by, e.g., nuclear magnetic resonance techniques 
(Constantinidis and Sambanis 1998; Stabler, Long et al. 2005; Stabler, Long et al. 2005) 
Previously, our lab engineered the human L-cell line, NCI-H716 to release insulin 
in response to nutrient administration (Tang and Sambanis 2003) and showed preferential 
transduction by adeno-associated virus for L-cells over enterocytes in a co-culture model 
(Tang and Sambanis 2004).  These studies laid the foundation for developing a method 
for gene delivery to L-cells in mixed cultures such as primary intestinal isolates.  But due 
to the complex anatomy of the intestinal epithelium and low percentage of L-cells, 
establishing primary cultures of enteroendocrine cells is difficult and these cultures do 
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not survive in vitro for extended periods.  Initially, we tried several protocols in attempts 
to isolate primary intestinal epithelial cells found in structures called crypts (APPENDIX 
A) but were unsuccessful in maintaining cultures with significant levels of viable cells.  
As these primary cultures made for poor test beds because of their severely limited shelf-
life, the focus of these studies was again placed on L-cell lines.  GLUTag cells are a 
reasonable choice as a model system and would represent a closer allograft model for 
mice than the previously investigated human NCI-H716 cells.  Thus, using GLUTag cells 
was a more direct avenue toward advancing L-cell mediated insulin therapy to a tissue-
engineered treatment for adult mouse models of IDD. 
The research in CHAPTER 3 was aimed at developing and characterizing a 
recombinant L-cell line for regulated insulin secretion.  This was approached by stable 
transfection of the murine GLUTag L-cell line with a vector encoding human insulin and 
neomycin resistance under the control of constitutive promoters.  The derived clonal cell 
line, GLUTag-INS, was then evaluated in vitro to determine if secretion of recombinant 
insulin and endogenous glucagon-like peptide-1 were regulated in the same manner by 
nutrient and putative secretagogues and to determine the time-course of insulin secretion.  
The work in CHAPTER 4 was to develop an implantable three-dimensional 
construct which retained the important insulin secretory properties of the cells and to 
study its behavior in vitro.  Hydrogels are frequently used in metabolic tissue engineering 
and have proven to be sufficient barriers against allograft rejection in mice.  As such, 
tissue engineered devices, in which GLUTag-INS cells were suspended in the natural 
agarose hydrogel evaluated against counterparts that incorporated either pre-aggregated 
GLUTag-INS spheroids or small intestinal submucosa.  Induced insulin secretion tests 
were performed on these types of constructs to determine which configuration was 
appropriate for maintaining this important characteristic of recombinant L-cell function. 
This project was further advanced in CHAPTER 5 when the tissue engineered 
pancreatic substitute based on recombinant L-cells and small intestinal submucosa 
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developed in CHAPTER 4 was implanted intraperitoneally in diabetic mice and the 
performance of the construct was evaluated by examining the retrieved constructs and the 
physiological effects on the mice.   
Each of the aforementioned chapters contains detailed motivation, research 
methods, results, and discussion.  General information on IDD and current and potential 
cell-based treatments are reviewed in CHAPTER 2.  Conclusions and potential future 
directions are discussed in CHAPTER 6.  Preliminary studies in understanding how best 
to transfer genetic material to L-cell lines can be found in APPENDIX B and a peripheral 
study looking to achieve L-cell specific gene expression through use of a cloned 
proglucagon promoter is discussed in APPENDIX C.  
In summary, this thesis is devoted to increasing the knowledge of developing 
recombinant β-cell surrogates for the treatment of IDD.  Enteroendocrine cells could 
potentially be of autologous origin (derived from the patient themselves), thus, 
potentially alleviating the immune acceptance challenges with allo- and xenogeneic cells.  
The ideal human therapy envisioned would entail surgical retrieval of intestinal stem cells 
(which give rise to enteroendocrine cells), genetically engineering these cells ex vivo, 
incorporating them into a tissue engineered device which may be monitored and retrieved 
if necessary, and re-implanting them into the patient.  This thesis evaluated the potential 
of a tissue engineered pancreatic substitute using a recombinant L-cell line.  Because 
these cells were not autologous in origin, a more direct path toward studying insulin-
secreting L-cells as part of a tissue engineered pancreatic substitute was possible.  An 
alternatively envisioned human therapy may rely on an engineered allogeneic cell source 
such as the one evaluated in this thesis given the inherent difficulties in working with 
primary L-cells or if a suitable number of intestinal stem cells could not be isolated and 
engineered by a tolerable size of resected intestine.  Alternatively, it may be that primary 
intestinal stem cells can be isolated and manipulated ex vivo, but may function better 
upon re-implantation if implanted by themselves.  Though this approach may not 
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facilitate their easy retrieval if needed, it would be preferred to other tissue engineering 






Diabetes is a significant health problem affecting an estimated 23.6 million people 
in the United States alone.  Among adults diagnosed with diabetes 27% report either 
taking insulin alone or in combination with oral medications (National Diabetes Fact 
Sheet, CDC 2007).  Those taking insulin may have either type 1 (juvenile) or type 2 
(adult onset) diabetes.  Type 1 diabetes results from the complete loss of insulin 
producing cell mass (β-cells of pancreatic islets) due to autoimmune attack, whereas 
when type 2 diabetes is diagnosed, the body is producing enough insulin but it is unable 
to use it.  This is a phenomenon called insulin resistance and overtime the body’s 
production of insulin also becomes impaired.  As insulin is required for maintaining 
blood glucose concentrations within a physiological range, exogenous insulin is 
necessary for all type 1 diabetics and many type 2 diabetics.  As such, insulin-dependent 
diabetes (IDD) is defined as those patients requiring the use of exogenous insulin to 
control blood glucose levels and the number of insulin-dependent diabetics in the U.S. is 
nearly 5 million people based on the most recent Figures provided by the CDC (National 
Diabetes Fact Sheet, CDC 2007).   
2.2 Insulin Therapy 
The tight physiological range of glucose in normal human subjects is maintained 
by the careful balance of the secretion of insulin and glucagon, hormones with 
antagonistic effects; and these rates of secretion are precisely regulated.  β-cells are 
responsible for maintaining a basal level of insulin during times of fast (including each 
night during sleep) and responding rapidly to the glycemic load following each meal.  
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The post-prandial response of β-cells is biphasic in nature with an initial rapid release 
phase which lasts for 5 -10 minutes, followed by a second phase in which the insulin 
secretion rate slowly increases over a period of several hours.  Thus in order for diabetic 
patients to mimic the insulin secretion profile by using exogenous insulin, multiple 
injections may be required.  In addition, several types of insulin are available which have 
varying characteristics of activity (onset, peak, and duration).  For example, a single 
injection of long-acting insulin, used to maintain the basal insulin level, has an onset time 
of one hour, no peak, and a duration of 20-26 hours, may be taken once daily (NIH 
2008).  Depending on the patient’s requirements, this may be supplemented with several 
injections of rapid-acting or short-acting insulin before a meal to mimic the post-prandial 
response.  Insulin, a protein hormone, is predominately delivered by subcutaneous 
injection or infusion by syringe or insulin pump, though Bentley Pharmaceutical’s 
intranasal spray, NasulinTM is in phase II clinical trials and other delivery routes for 
insulin including an insulin pill, buccal sprays, and a transdermal patch are under 
investigation (NIH 2008). 
Although diabetes is considered a chronic disease, treatable with daily injections 
of insulin and careful monitoring of one’s diet, even the most vigilant insulin therapy 
cannot reproduce the precise metabolic control present in the non-diseased state.  The 
poor temporal match between glucose load and insulin action leads to a number of 
complications including increased risk of heart disease, kidney failure, blindness, 
amputation due to peripheral nerve damage, diabetic ketoacidosis, or hyperosmolar coma 
(National Diabetes Fact Sheet, CDC 2005).  A 10-year, multi-center study conducted by 
the Diabetes Control and Complications Trial Group (1993), suggest that aggressive 
monitoring and insulin therapy can postpone the onset of these secondary complications, 
but that exogenous insulin therapy alone cannot prevent them.  Cell-based therapies, 
which provide continuous regulation of blood glucose, would provide more physiological 
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control thereby potentially alleviating many of the diabetes-related health problems and 
revolutionizing diabetes care. 
2.3 Current and Future Cell-Based Therapies 
Several directions are being considered for cell-based therapies of IDD including 
implantation of allogeneic or xenogeneic islets; differentiation of adult or embryonic 
stem or progenitor cells into insulin-secreting cells; genetic engineering of autologous 
non-β-cells; implantation of encapsulated insulinoma cell lines; and in vivo gene therapy.  
The first three approaches will be discussed in this chapter, and the variety of potential 





Figure 2.1 The spectrum of cell-based therapies for the treatment of insulin-dependent diabetes. 
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2.3.1 Islet Transplantation 
2.3.1.1 Allogeneic Islet Transplantation 
Islet transplantation involves the isolation of islets from a donor pancreas and the 
subsequent re-implantation of the purified islets into the liver of the diabetic recipient via 
the portal vein as shown in Figure 2.2.  This procedure is far less invasive than the 
surgery required for the implantation of the whole organ, yet still requires the use of life-
long immunosuppressive drugs to prevent rejection of the donor tissue.  Sometimes, the 
side-effects of the drugs used to prevent rejection are deemed worse than the 
inconvenience of exogenous insulin therapy and the threat of secondary complications. 
 
 
The islet transplantation protocol developed by physicians at the University of 
Edmonton (Shapiro, Lakey et al. 2000; Logberg, Sgan et al. 2003) dramatically improved 
the survivability of allogeneic islet grafts, with 80% of patients being insulin independent 
one year post-transplantation (Bertuzzi, Marzorati et al. 2006).  A five year follow-up 
however, revealed that although 80% of patients still had detectable C-peptide, only 10% 
Figure 2.2 Overall process of islet transplantation.  Islets are purified from the donor 
pancreas and later, infused into the portal vein of the diabetic recipient so that they 
become lodged in the microvasculature of the liver. Illustration by Giovanni Maki 
(Naftanel and Harlan 2004). 
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remained insulin independent, indicating that there was a progressive decline in graft 
function (Bertuzzi, Marzorati et al. 2006).  Reasons for loss of islet function after 
transplantation include (1) insufficient transplanted β-cell mass, (2) allograft rejection 
due to inflammation, (3) recurring autoimmunity, (4) incompatibility of islet implantation 
site, and (5) the toxicity of the immunosuppressive regiment (Lee, Grossman et al. 2008). 
Even as scientists overcome the reasons for failed islet transplantations, the 
application of this therapy is still limited to a very small subset of the diabetic population 
due to the supply of donor islets.  Using current techniques and practices the number of 
patients treated by islet transplantations in a typical year are optimistically estimated at 
1,000 to 2,000 (Ren, Jin et al. 2007).  The need for at least two cadaveric donor 
pancreases per patient and the worsening trend of the donor to recipient ratio contribute 
to keeping this number low.  This situation is so restricted because islet cells do not 
significantly expand their population size in culture.  One could imagine that donation of 
a partial pancreas from a living relative may help, and indeed there has been one reported 
case of successful living donor islet transplantation performed at Kyoto University 
Hospital in Japan (Matsumoto, Okitsu et al. 2005).  The one year follow-up of these 
patients even indicated that the recipient was still insulin-independent and the donor had 
recovered quickly with no adverse effects from the partial pancreatectomy (Matsumoto, 
Okitsu et al. 2006), but given the risk to the living donor during surgery and anesthesia, 
living donor islet transplantations are only considered for patients with high incidence of 
life-threatening hypoglycemic unawareness and when cadaveric islets donors are 
unavailable.   
Another problem with islet transplantation is the need for life-long treatment with 
immunosuppressant drugs.  This issue is compounded by the fact that tacrolimus is a 
nephrotoxic agent, making proper kidney function a prerequisite for islet transplantation 
(Bertuzzi, Marzorati et al. 2006).  Since kidney failure is already a complication of 
diabetes, this excludes a great number of diabetics from this therapy and increases the 
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incidence of kidney failure, with 5% of kidney function lost each year among recipients 
(Ren, Jin et al. 2007).  Additionally the immunosuppressive drugs used after 
transplantation have diabetogenic properties and may account for some of the progressive 
loss of β-cells (Bertuzzi, Marzorati et al. 2006; Ren, Jin et al. 2007).  Despite 
improvements in islet transplantations, there appear to be insurmountable barriers for 
widespread application of this therapy. 
2.3.1.2 Xenogeneic Islet Trasnplantation 
The issue of limited supply of donor pancreases could be relieved if islets derived 
from animal sources (xenografts) could be made into a viable transplant.  Porcine islets 
have been the subject of intense research, as glycemic regulation is very similar between 
pigs and humans and porcine insulin was used for many years as a source of exogenous 
insulin (MacKenzie, Hullett et al. 2003).  However, repressing the immune rejection of a 
xenograft is a formidable challenge, and the mechanisms of xenograft rejection are not 
entirely understood (MacKenzie, Hullett et al. 2003). In addition, concern of transmission 
of infectious agents (most notably of the porcine endogenous retrovirus, PERV) from the 
graft to the host is of paramount concern.  In an effort to reduce the risk of disease 
transmission and improve immune acceptance, encapsulation of islets has been 
investigated by a number of groups (Lim and Sun 1980; Sambanis 2003; Cui, Barr et al. 
2004).  Long-term survival of porcine grafts has been challenging and severely limited 
due to lack of biocompatibility, limited immuno-protective properties, and hypoxia (de 
Groot, Schuurs et al. 2004).  In regard to protecting the host from PERV transmission, 
however, encapsulation in alginate polylysine capsules was sufficient in preventing the 
leakage of viral particles or RNA in vitro (Elliott, Escobar et al. 2000) and a human 
subject receiving encapsulated neonatal porcine islets through a Swedish clinical trial 
showed no evidence of porcine viral or retroviral infection 9.5 years post implantation 
(Elliott, Escobar et al. 2007).  A device based on functional and immune-acceptable 
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xenogeneic islets would lend itself to wide-spread application, but the incomplete 
understanding of immune rejection at the fundamental level has so far hampered its 
development. 
Apart from islet transplantation, several other directions are being considered for 
cell-based therapies of IDD including differentiation of adult or embryonic stem cells into 
insulin-secreting cells and genetic engineering of autologous non-β-cells.   
2.3.2 Differentiation of Stem Cells to β-Cells 
Stem cells differentiated into replacement β-cells constitute an attractive approach 
toward resolving the cell source issue for islet transplantation.  By definition, stem cells 
possess a nearly unlimited regenerative capacity due to the property of self renewal, and 
may be coaxed to differentiate into specialized cell types.  Indeed, the very nature of the 
disease makes IDD a good target for stem cell therapy, in that just a single protein is 
deficient and a single cell population is responsible for production of that missing protein. 
Stem cells or progenitor cells have been isolated from a wide variety of tissues, 
including both embryonic and adult sources.  These cells are often characterized by the 
variety of cells that they can give rise to and some of the various sources of stem cells are 




Totipotent stem cells can give rise to every cell found in the body including the 
placental tissue needed to support the growing embryo.  Pluripotent stem cells are 
capable of giving rise to cells from all three germ layers, while further down this scale 
multipotent stem cells are limited to progeny of a particular lineage found during normal 
development.  Exceptions to the definitions just stated do exist, as certain stem cells and 
even adult cells have been shown to transdifferentiate—that is, to cross the lines traced 
by normal developmental lineages.  Understandably, the more non-committed a stem cell 
is to a particular lineage, the more complex the protocol needed to reliably differentiate 




Figure 2.3 The origin, isolation, and specialization of embryonic stem cells.  
Illustration by Jen Philpott (Chaudry 2004). 
adult stem cells 
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2.3.2.1 Differentiation of Embryonic Stem Cells to β-Cells 
Pluripotent stem cells include both embryonic stem cells (ESCs) retrieved from 
the inner cell mass of the developing blastula and a select few adult stem cells, such as 
those isolated from umbilical cord blood.  The generation of insulin-secreting cells from 
pluripotent ESCs is hampered by the fact that pancreatic-cells appear late during 
embryonic development. Thus generation of insulin-secreting cells from ESCs involves 
the sequential activation and deactivation of a considerable number of genes controlling 
the generation of endoderm lineage cells, the subsequent generation of the precursors of 
pancreatic cells, and finally the insulin-secreting cells.  Despite this difficulty there has 
been some success in differentiating ESC into insulin producing cells in vitro (Lumelsky, 
Blondel et al. 2001; Hori, Rulifson et al. 2002; Moritoh, Yamato et al. 2003) and in using 
the derived cells to normalize glycemia in diabetic mice (Soria, Roche et al. 2000; Kim, 
Gu et al. 2003).  It has been pointed out, however, that many of the insulin-positive cells 
in ESC cultures may be the product of insulin uptake from the culture medium and not 
due to endogenous production (Hansson, Tonning et al. 2004).  The presence of C-
peptide distinguishes de novo insulin synthesis from artifact and there are some genuine 
insulin-producing cells derived from ESCs. 
A major concern with ESCs is the potential of teratoma development arising from 
undifferentiated cells which may be inadvertently implanted along with the differentiated 
β-like cells.  To protect against this threat, ways to screen stem-cell derived products for 
teratoma potential have been investigated (Lawrenz, Schiller et al. 2004).  Screening 
alone does not altogether eliminate this risk and as such, genetic engineering of stem cells 
with genes that allow their in vivo monitoring and targeted destruction if need be are also 
being investigated (Cao, Drukker et al. 2007).  Though these, or other, engineered safety 
measures enhance the potential of success of stem cell-based therapies, they also enhance 
the overall complexity.  In addition to the threat of cancer development, the β-cell freshly 
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derived from embryonic stem cells are at risk of allograft rejection or autoimmune 
destruction, as would be transplanted islets. 
2.3.2.2 Differentiation of Adult Stem Cells to β-Cells 
Adult stem cells have been better received than embryonic stem cells because 
their use does not require the destruction of embryos—a major ethical stumbling block 
for ESC therapy—and they could potentially be retrieved from the patients themselves, 
thus greatly reducing the risk of rejection, though the possibility of autoimmune rejection 
inherent to type 1 diabetes cannot be eliminated.  As mentioned previously, stem cells 
from umbilical cord blood are considered adult stem cells, yet are also pluripotent and in 
vitro differentiation of umbilical cord blood cells into insulin-producing cells has been 
reported (Sun, Roh et al. 2007).  Most adult stem cells, however, are multipotent and are 
classified by their tissue of origin.  For regenerating β-cells, the most obvious adult stem 
cell source is pancreatic duct cells.  These cells seem to be easier to fully differentiate but 
are more difficult to proliferate (Soria, Bedoya et al. 2005) and there is still considerable 
debate over whether regeneration of β-cells is due to pancreatic stem cells or replication 
of existing β-cells.  Though there is evidence to suggest that pancreatic ductal tissue may 
be directed to differentiate into glucose responsive islet tissue  (Bonner-Weir, Taneja et 
al. 2000), more recent work has demonstrated that regeneration of β-cells is due to 
replication of adult cells and not attributed to pancreatic stem cells (Dor, Brown et al. 
2004).   
Another obvious source for stem cells used for β-cell regeneration is the liver, as 
both the liver and pancreas arise from the same cell population in the embryonic 
endoderm. Adult liver cells have even been made to transdifferentiate into functional 
insulin-producing cells under the appropriate conditions (Yang 2006).  Bone marrow 
derived stem cells have also been used toward this purpose with some success (Chen, 
Jiang et al. 2004).  The spleen has also been touted as a source for stem cells capable of 
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differentiation into insulin producing cells. Kodama et al. found that when splenocytes 
were delivered along with islet transplantation in NOD mice, the mice regenerated islets 
in the pancreas which were of donor origin, and that when the islet transplant was 
excised, the mice remained normoglycemic (Kodama, Kuhtreiber et al. 2003).  But when 
others tried to reproduce this work, it was found that the reversal of diabetes was not 
attributable to the donor spleen cells (Chong, Shen et al. 2006; Nishio, Gaglia et al. 2006; 
Suri, Calderon et al. 2006). 
Though exciting developments will likely be seen in the area of stem cell therapy 
for IDD, there are still many unknown factors and processes associated with the 
differentiation process and to date, deriving β-cells from differentiated stem cells has 
been fraught with difficulty and has not given rise to a reliable method for regenerating 
islet cell mass. 
2.3.3 Transdifferentiation and Metaplasia 
Until recently it was thought that differentiated cells could only be produced from 
embryonic or adult stem cells or progenitor cells.  There is now a growing body of 
evidence that suggests that differentiated cells of one type can be converted to another 
type through a process called transdifferentiation (or metaplasia) (Thowfeequ, Myatt et 
al. 2007; Eberhard and Tosh 2008).  This phenomenon has understandably generated 
huge interest because of the potential for adult cells, which could be easily collected, to 
be converted to other medically important cell types to repair diseased or damaged 
tissues. 
For generating β-cell replacements for IDD, the differentiated adult cells that are 
investigated for this process are most commonly liver cells and exocrine pancreas cells, 
as these sources share much of the developmental lineage with the endocrine pancreas.  
The human PANC-1 and rat ARIP pancreatic ductal cell lines were shown to be able to 
differentiate into insulin-secreting endocrine cells by expression of Pdx-1 and exposure to 
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GLP-1 (Hui, Wright et al. 2001).  Functional β-like cells have been generated from 
cultured adult exocrine pancreatic cells treated with leukemia inhibitory factor and 
epidermal growth factor (Baeyens, De Breuck et al. 2005).  Recently, a similar approach 
to reprogramming exocrine pancreatic tissue in vivo through expression of a combination 
of transcription factors (Ngn3, Pdx-1, and Mafa) has received significant attention (Zhou, 
Brown et al. 2008).  Successful in vivo transformation of hepatocytes using some of the 
same transcription factors has also been reported (Ber, Shternhall et al. 2003; Kojima, 
Fujimiya et al. 2003; Imai, Katagiri et al. 2005; Kaneto, Matsuoka et al. 2005; Kaneto, 
Nakatani et al. 2005). 
The fundamental understanding of how these transformations take place however 
is still a subject of intense investigation and many questions remain to be answered prior 
to use of this sort of therapy for human clinical studies. 
2.3.4 Genetic Engineering of Autologous Non-β-cells 
The use of non-β-cells from the patient themselves relaxes the requirements of 
availability and immune acceptance but is hindered by the need to recapitulate the 
complex regulatory system of insulin production and secretion inherent to the β-cell.  The 
first attempt at engineering non-β-cells for insulin production, focused on endocrine cells 
of the pituitary because they efficiently process proinsulin to insulin and can secrete 
bioactive insulin in a regulated manner after they are engineered to express proteins 
commonly referred to as glucose sensors: the phosphorylating enzyme glucokinase (GK) 
and the glucose transporter GLUT2 (Hughes, Quaade et al. 1993; Motoyoshi, Shirotani et 
al. 1998).  Since pituitary cells are not naturally glucose responsive, and many 
endogenous products are not compatible with prandial metabolism, unless efforts are 
made to knock down endogenous hormone expression, over-secretion of the native 
hormones, such as adrenocorticotropic hormone (ACTH), may upset the metabolic state 
of the patient.  Autologous neuroendocrine tissues are also difficult to obtain or transduce 
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in vivo.  Other, more easily accessible cells, such as muscle (Yin and Tang 2001) and 
skin (Lei, Ogunade et al. 2007) cells have also been targets for insulin gene therapy.  
These non-endocrine cells, however, require the use of recombinant insulin that is either 
bioactive as a single chain (Lee, Kim et al. 2000) or able to be cleaved by the ubiquitous 
endopeptidase, furin (Groskreutz, Sliwkowski et al. 1994).  In the situation of a bioactive 
single chain there is a lack of C-peptide, a product which normally connects the A and B 
chains of insulin prior to post-translational modification and is released in equimolar 
amounts by cells with proper processing of proinsulin to insulin by prohormone 
convertases (PC).  Although C-peptide is not present in pharmaceutical preparations of 
insulin, C-peptide has many beneficial effects on preventing complications normally 
associated with IDD (Rebsomen, Khammar et al. 2008; Sima and Kamiya 2008).  
Furthermore, these non-β-cell sources are still inadequate, as they do not possess the 
elements necessary for nutrient-regulated secretion, and so, may only be used to fulfill 
the need for basally secreted insulin.  Like β-cells, liver cells (hepatocytes) are glucose 
sensitive, making them a likely candidate for engineering of non-β-cells.  Indeed, success 
has been seen in animal models in which hepatocytes are genetically engineered to 
secrete insulin that is transcriptionally regulated by a glucose and insulin sensitive 
promoter (Huang, Thule et al. 1995; Thule, Liu et al. 2000; Thule and Liu 2000; Olson, 
Paveglio et al. 2003).  Transcriptional regulation, however, is sluggish to turn on and off 
insulin production and so, cannot provide the acute post-meal insulin release considered 
necessary for glycemic normalization in higher animals and, eventually, humans.  
Improvements in the responsiveness of this system have been accomplished through the 
destabilization of the insulin messenger RNA (Tang and Sambanis 2003). 
A better solution may be to engineer insulin production in endocrine cells of the 
gastrointestinal tract (enteroendocrine cells), as these cells already share a number of the 
elements needed for regulated secretion and play a role in post-prandial processes. 
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2.3.5 Enteroendocrine Cells for the Treatment of Diabetes 
The importance of enteroendocrine cells (and in particular, L-cells) was first put 
forward by Creutzfeldt whose primary interest in enteroendocrine cells was for the 
prospect of using glucagon-like peptide-1 (GLP-1) for the treatment of type 2 diabetes 
(Creutzfeldt 1974).  The incretins GLP-1 (from L-cells) and glucose-dependent 
insulinotropic polypeptide, GIP (from K cells) are released after a meal to potentiate 
insulin production from the pancreas.   
As with β-cells, enteroendocrine cells are polar, with sensing microvilli on their 
luminal side and secretory granules docking at the basolateral side, adjacent to capillaries.  
Enteroendocrine cells secrete incretin hormones in a tightly controlled manner that 
parallels the secretion of insulin by β-cells, following oral glucose load as shown in 





Figure 2.4 Gastric emptying and release of incretin hormones after glucose 
ingestion in healthy human subjects (Schirra 1996) 
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L-cells produce GLP-1 and GLP-2 and secrete them in parallel in adult humans 
after oral feeding. GLP-1 and GLP-2 are released in a biphasic manner with a rapid initial 
increase occurring within 15 minutes, followed by a second increase after about one hour 
(Burrin, Petersen et al. 2001).  
In addition to amenable secretion characteristics and a natural connection to 
metabolism, enteroendocrine cells are also appealing due to their location within the 
intestine.  The intestinal tract is an attractive target because of its large size and 
accessibility.  In fact the combined mass of the different enteroendocrine cell types make 
up the largest endocrine organ in the body (Wang, Liu et al. 2004).  Despite the 
advantages, intestinal gene therapy is difficult because of the harsh conditions present in 
the stomach and intestine, and the intestinal epithelium renews rapidly, with the entire 
epithelium being replaced every three to five days (Fujita, Cheung et al. 2004).  In 
addition, the epithelium is difficult to transduce because of its intrinsic function as the 
body’s barrier to external threats (Tang, Sambanis et al. 2005). 
Because of the unique connection between incretins and insulin, engineering of 
enteroendocrine cells for regulated insulin secretion arises as an appealing approach for 
IDD treatment in terms of the dynamic release of insulin, as well as the compatibility of 
incretins and insulin in glycemic normalization. Work by Cheung et al. in 2000  
demonstrated that insulin produced and secreted by genetically modified intestinal K 
cells prevented these transgenic mice from becoming diabetic after injection with 
streptozotocin (STZ) (Cheung, Dayanandan et al. 2000).  Similarly, transgenic mice 
which produced human insulin in gastric G cells, displayed meal-regulated increase in the 
level of transgenic insulin and corresponding decrease in blood glucose levels (Lu, 
Sternini et al. 2005).  These are important proof-of-concept studies which showed that 
enteroendocrine cell-produced insulin can provide regulation of blood glucose levels.   
Despite the straight-forward promise of using enteroendocrine cells for insulin 
gene therapy, applying genetic engineering methodologies in vivo to enteroendocrine 
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cells remains a challenging problem.  This is due largely in part to the complex anatomy 
of the intestinal epithelium, which is made up of fingerlike projections called villi and 
invaginations of the gut mucosa called crypts.  Enteroendocrine cells are found at the 









Although L-cells are the most abundant enteroendocrine cell, enteroendocrine 
cells make up only about 1% of the total cell population of the intestinal epithelium 
(Wang, Liu et al. 2004) with adsorptive enterocytes being the major cell population.  The 
intestinal epithelium is also a tissue with rapid turnover.  Unlike many endocrine cells in 
various glands throughout the body that differentiate early in life and turnover slowly, 
enteroendocrine cells actively self-renew and differentiate throughout the life of an 
animal from a large reservoir of stem cells (Schonhoff, Giel-Moloney et al. 2004).  These 
stem cells are also localized in the base of crypts and serve the function of renewing the 
entire epithelium (Winton 2001).  Recently, the discovery of the intestinal stem cell 
marker, Lgr5, a transmembrane protein with a large extracellular domain for ligand 
binding, has opened doors to a number of important studies that were not possible just a 
couple of years ago  (Barker, van Es et al. 2007).  Markers suggested previously 
Figure 2.5 Structure of a single colonic crypt.  The four cell constituents 
(enterocyte, goblet cell, gut stem cell, and enteroendocrine cell) are indicated 








included: telomerase (Booth and Potten 2000); Musashi and Hes-1 (Kayahara, Sawada et 
al. 2003; Potten, Booth et al. 2003); integrins (Beaulieu 1992); BMPR1α and phospho-
PTEN (He, Zhang et al. 2004); DCAMKL1 (Giannakis, Stappenbeck et al. 2006); and 
Eph receptors (Batlle, Henderson et al. 2002), but none of these studies showed definitive 
proof that the positive-staining cells were functional intestinal stem cells (Montgomery 
and Breault 2008).  This marker can now be envisioned to develop a reliable method of 
targeting intestinal stem cells for gene delivery, to provide enduring insulin expression 
within the intestinal epithelium.  Stem cells of the small intestine have genome protective 
measures to ensure the accuracy of the copies made during the many divisions they must 
undergo in their lifetime.  Though this may provide a level of safety when targeted by 
genetic engineering approaches to derive insulin-producing tissue to treat diabetes 
(Fujita, Cheung et al. 2004), it may also hinder attempts to efficiently deliver genetic 
material.  Despite the challenges inherent to working with intestinal stem cells, they 
present a great opportunity; harnessing these stem cells may provide enduring insulin 
expression.  
2.3.6 Autoimmunity in Type 1 Diabetes 
Any cell therapy for IDD must be concerned with what would happen to the 
engineered surrogate β-cells or newly differentiated β-cells upon implantation into the 
diabetic host.  Particularly for subjects with type 1 diabetes, if autoimmunity to β-cells 
remains, how will this affect the β-cell or β-cell-like tissue?  It is reasonable to suspect 
that regenerated β-cells would be subject to the same processes that caused the initial 
onset of the disease, but β-cell surrogates may lack the elements that would be required 
for recognition by autoantigen-reactive T-cells. 
Multiple islet molecules are the target of autoimmunity in man and in animal 
models of type 1 diabetes (Wegmann, Norbury-Glaser et al. 1994; Lieberman, Evans et 
al. 2003).  The autoantigens implicated in type 1 diabetes include insulin, glutamic acid 
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decarboxylase (GAD), the protein tyrosine phosphatase-related islet antigen 2 (IA-2), and 
the zinc transporter of the insulin secretory granules (Slc30A8) (Knip and Siljander 
2008).  Positive expression of a single autoantibody usually represents harmless non-
progressive β-cell autoimmunity, whereas the presence of two or more autoantibodies 
reflects a progressive process that only rarely reverts (Knip and Siljander 2008).  It is not 
clear, however, whether any of the target molecules are essential for the destruction of β-
cells and there is no consensus whether or not there is any primary autoantigen.  
Understandably, insulin remains the most suspected candidate because its encoding gene 
is only expressed in the cells that are specifically targeted during autoimmune attack 
(Pasquali, Giannoukakis et al. 2008).   
 Interestingly, in transgenic nonobese diabetic (NOD) mice that secreted mature 
insulin via the regulated secretion pathway in pituitary cells, these cells were not targeted 
or destroyed by cells of the immune system, unlike pancreatic β-cells (Lipes, Cooper et 
al. 1996).  This suggests that expression of insulin alone in non-β-cells is not sufficient to 
induce autoimmune destruction in an autoimmune model for diabetes.  As such it is 
expected that, although insulin is a suspected autoantigen, insulin-expressing intestinal L-
cells will be able to avoid destruction by autoimmune processes. 
2.4 Studying L-Cells In Vitro 
Due to the complex anatomy of the intestinal epithelium and low percentage of L-
cells, establishing pure primary cultures of these enteroendocrine cells is difficult and 
these cultures often have low viability in vitro.  Thus, primary L-cell preparations are 
short-lived and heterogeneous, making analysis of primary L-cells in vitro very 
challenging.  The fetal rat intestinal cell (FRIC) culture is the only primary cell model 
that has been developed for in vitro studies of intestinal cells, and though it is a 
heterogeneous, poorly characterized cell population, it has provided insight about primary 
epithelial cells in a number of studies (Anini, Hansotia et al. 2002; Ni, Anini et al. 2003).  
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There are still no standard protocols for isolating adult primary cultures of intestinal L-
cells.   
A limited number of immortalized cell lines, however, have been developed for 
studying GLP-1 secretion by L-cells that have proven to be quite useful to date.  Two of 
these continuous cell lines have been derived from intestinal tumors of transgenic mice 
(the GLUTag and STC-1 cell lines) and a third is derived from a poorly differentiated 
human cecal carcinoma (the NCI-H716 cell line).  The NCI-H716 cells have been used in 
a number of studies as a model enteroendocrine, L-cell population (Reimer, Darimont et 
al. 2001; Tang and Sambanis 2003; Tang and Sambanis 2004).  These cells are cultured 
as floating aggregates prior to the induction of differentiation by exposure to specific 
extracellular matrix proteins found in Matrigel (de Bruine, Dinjens et al. 1993). Once 
differentiated, these L-cells grow as monolayers and respond to nutrient stimulation in 
the form of peptones (meat hydrolysates).  However, Cao et al. (Cao, Flock et al. 2003) 
reported that this cell line has aberrant regulation of the proglucagon promoter and, as 
such, is a poor experimental system to investigate the proglucagon promoter for cell type-
specific expression of a gene therapy product.   
Brubaker et al. have investigated the regulated secretion of GLP-1 from L-cells 
using a heterogeneous mouse cell line, STC-1 (Brubaker, Izzo et al. 2003).  Similarly, 
Hira et al. used the STC-1 cell line to investigate cholecystokinin (CCK) release 
following dietary protein stimulation (Hira, Hara et al. 2003).  Boylan et al. used this 
same cell line transfected with a mammalian selection marker driven by a K cell-specific 
promoter to generate a more homogeneous K cell population (Boylan, Jepeal et al. 1997).  
More recently, the STC-1 cell line has been genetically modified to express insulin in K 
cells under control of the GIP promoter, and these cells were shown to reverse 
hypoglycemia when transplanted under the kidney capsule (Han, Lee et al. 2007) or 
subcutaneously (Zhang, Yao et al. 2008) in diabetic mice.  In a separate study of a 
genetically engineered STC-1 line, cells doubly transfected for neomycin resistance and 
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insulin expression, both under control of GIP promoters did not display glucose-regulated 
release of insulin or GIP (Ramshur, Rull et al. 2002), though this is likely an artifact of 
the stable clone selection processes.   
GLUTag cells, a murine cell line, are a homogeneous population of L-cells that 
have been successfully employed by a number or laboratories for the study of L-cells’ 
regulated secretion (Drucker, Jin et al. 1994; Brubaker, Schloos et al. 1998; Cordier-
Bussat, Bernard et al. 1998; Nian, Drucker et al. 1999; Dhanvantari, Izzo et al. 2001; 
Reimann and Gribble 2002).  This cell line has been used specifically in 
electrophysiology studies to explore the stimulated secretion pathway of enteroendocrine 
cells as well as studies to determine glucagon gene regulation in enteroendocrine cells.  
In comparing GLUTag cells to primary L-cell cultures and in vivo models, Brubaker et 
al. found GLUTag cells to respond appropriately to the regulatory mechanisms 
controlling intestinal GLP-1 secretion, making this a very useful L-cell model (Brubaker, 
Schloos et al. 1998). 
2.5 Tissue Engineered Pancreatic Substitutes 
Tissue engineering is an interdisciplinary field that applies the principles of 
engineering and the life sciences toward the development of biological substitutes that 
restore, maintain, or improve tissue function (Langer and Vacanti 1993). Tissue 
engineering may use one of three basic strategies: isolated cells or cell substitutes, tissue 
inducing substances, or cells placed within matrices.  For the purposes of IDD, the first 
approach is already being applied in islet transplantation.  Since β-cells do not 
significantly expand in cell number in vivo the second approach of a tissue inducing 
substitute is considerably more challenging.  As discussed previously, adult stem or 
progenitor cells may reside within the pancreas and if suitable cues were provided to 
these cells, potentially though presentation of the appropriate growth factors via a 
biomaterial, regeneration of β-cell mass would be theoretically possible.  Alternatively, it 
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has been reported that exocrine pancreas tissue can be induced to take on a β-cell 
phenotype through metaplasia (Zhou, Brown et al. 2008)  so a similar approach could be 
envisioned to target those cells.  In all of these cases, if the regenerated β-cells are 
recognized by the autoimmunity in type I diabetic subjects, a method to prevent 
autoimmune destruction of the cells would be critical.  The biological understanding of 
stem or progenitor cell differentiation and metaplasia is still in its infancy, however and 
as such, so is this approach to tissue engineering.   
The third approach in which cells are combined with a biomaterial is the most 
commonly utilized tissue engineering strategy for IDD.  This is because when cells 
displaying class I and II major histocompatibility (MHC) markers are transplanted 
between unrelated individuals, it normally results in the rejection of those cells.  The 
expression of type II MHC has been minimized for skin tissue by passaging the cells 
during in vitro culture (Thivolet, Faure et al. 1986).  Unfortunately, this approach is not 
possible for cells of the pancreatic islets, as they do not propagate in culture and so hiding 
the MHC markers by coating with a polymeric membrane or entrapment within a 
membrane is a more suitable approach to lessening the need for immunosuppressive 
drugs. 
The pore size of the polymeric biomaterial or membrane is designed such that 
small molecules including metabolites essential to cell survival and function (e.g. oxygen 
and glucose) and insulin can pass freely, while most immune response elements 
(antibodies and lymphocytes) are denied entry.  Thus the encapsulated cells can sense the 
surrounding glucose levels and respond with insulin secretion accordingly while being 
partially hidden from the host’s immune system.  One commonly used method involves 
the encapsulation of cells or cell aggregates in alginate microbeads (Lim and Sun 1980) 
which are typically 400-800 µm in diameter.  These microbeads are usually implanted in 
avascular sites such as the peritoneal cavity.  The commonly employed site of islet 
transplantation (hepatic vasculature) is unavailable for microbead transplantation due to 
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the dangerous rise in intraportal pressure that would result due to the relatively large size 
of the microbeads.  As such, cells entrapped in large devices are often well beyond the 
200 µm distance from the capillaries that is normally seen in the body and thus diffusion 
of nutrients and especially oxygen may limit the functionality of cells implanted in such 
devices.  Even sublethal levels of hypoxia can have deleterious effects on ATP-dependent 
cell functions such as insulin secretion (Dionne, Colton et al. 1993; Papas, Long et al. 
2000; Wilson and Chaikof 2008).   
To reduce mass transport limitations recent efforts have focused on developing 
conformal coatings of micron and submicron scale in individual cells or cell aggregates 
(Wilson, Cui et al. 2008), incorporating vasculature within tissue engineered constructs, 
or transplanting  grafts into prevascularized sites.  For instance delivery of vascular 
endothelial growth factor and fibroblast growth factor-2 via a scaffold consisting of 
nanofibers led to improved engraftment of islets during implantation to the omentum due 
to an increase in neovasculature within the construct (Stendahl, Wang et al. 2008).  
Alternatively, digested vascular tissue was added directly to collagen gels of a tissue 
engineered construct and the presence of the prevascularized collagen was found to 
improve the viability and metabolic function of encapsulated islets (Hiscox, Stone et al. 
2008). 
2.6 Animal Models for IDD 
Diabetic mouse models have been used extensively in the literature and are 
essential tools for evaluating the ability of pancreatic substitutes to regulate glucose 
metabolism in vivo.  The two most commonly used models for IDD are the STZ-induced 
mouse model and the non-obese diabetic (NOD) mouse (Atkinson and Leiter 1999).  In 
the first model, STZ is injected into mice and this drug causes specific ablation of β-cells, 
thus inducing the onset of a diabetic state in the mouse model. STZ is an agent used in 
the treatment of metastasizing pancreatic islet tumors and diabetes research. The structure 
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of STZ is comprised of a glucose molecule with a highly reactive nitrosurea side chain.  
It is thought that the glucose moiety directs it to pancreatic β-cells where it binds to a 
membrane receptor to generate structural damage to the cells, though intracellular 
responses to the drug also assist in cell death (McNeill 1999).  Alternatively, the NOD 
model is an inbred mouse strain commonly used as a model for autoimmunity in diabetes.  
NOD mice have high incidence of insulitis (infiltration of the pancreas with leukocytes), 
which in many animals leads to the spontaneous development of IDD when they are 
between 12 and 30 weeks old (Rees and Alcolado 2005).  NOD mice, however, show 
abnormalities in addition to those observed in the pancreas.  Autoimmune inflammation 
of the thyroid and inflammation of submandibular and lacrimal glands also occur 
frequently which lends this experimental model to the study of other autoimmune 
diseases like multiple sclerosis and Sjögren’s syndrome.  Due to these complications, the 
STZ is also very useful despite the absence of autoimmune rejection of the β-cells.   
In addition to the well established diabetic animal models, the enteroendocrine 
cells of the mouse are remarkably similar to those in humans (Schonhoff, Giel-Moloney 
et al. 2004), making it likely that the insights learned from the mouse may contribute to 
our understanding of enteroendocrine cell insulin treatment for IDD in humans. 
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CHAPTER 3 
INSULIN-SECRETING L-CELLS FOR THE TREATMENT OF 
INSULIN-DEPENDENT DIABETES1 
 
Cell-based treatments for insulin-dependent diabetes (IDD) may provide more 
physiologic regulation of blood glucose than daily insulin injections, thereby reducing the 
occurrence of secondary complications associated with diabetes.  An autologous cell 
source is especially attractive for regulatory and ethical reasons, in addition the need for 
immunosuppresion is ameliorated.  Enteroendocrine L-cells, exhibit regulated secretion 
in response to physiologic stimuli and their endogenous products are fully compatible 
with prandial metabolism.  The aim of this study was to develop a surrogate β-cell based 
on this potentially autologous cell type and evaluate the function of the resulting 
genetically modified L-cells.  Murine GLUTag L-cells were transfected with a plasmid 
co-expressing human insulin and neomycin resistance and the stable cell line, GLUTag-
INS, was established.  Secretion properties of GLUTag-INS cells were investigated in 
vitro through induced secretion tests using meat hydrolysate or 3-isobutyl-1-
methylxanthine and forskolin as secretagogues.  GLUTag-INS cells rapidly co-secreted 
recombinant insulin and endogenous GLP-1 in response to metabolic cues from the 
surrounding medium and demonstrated efficient processing of proinsulin to insulin. 
3.1 Introduction 
The use of autologous, non-β-cells for treatment of IDD would eliminate the need 
for immunosuppresion currently required for other cell therapies and would relax the 
constraint of tissue supply.  Though studies have achieved insulin secretion in non-β-
cells, attempts to restore normoglycemia have fallen short of reconstructing the complex 
                                                 
1 This work has been published: Bara and Sambanis (2008). Biochem Biophys Res Commun 371(1):39-43 
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sensory and regulatory machinery unique to β-cells.  Pituitary cells were engineered for 
insulin production because they efficiently process proinsulin to insulin and can secrete 
insulin in a regulated manner upon expression of GK and GLUT2 (Hughes, Quaade et al. 
1993; Motoyoshi, Shirotani et al. 1998).  Pituitary products, however, are not compatible 
with prandial metabolism and aberrant over-secretion of the native hormones may upset 
the metabolic state of the patient.  Neuroendocrine tissues are also difficult to obtain for 
ex vivo manipulation and difficult to transduce in vivo.  More easily accessible targets, 
such as muscle (Yin and Tang 2001) and skin (Lei, Ogunade et al. 2007) have also been 
used for insulin gene therapy.  These cells, however, require the use of recombinant 
insulin that is either bioactive as a single chain (Lee, Kim et al. 2000) or able to be 
cleaved by a ubiquitous endopeptidase (Groskreutz, Sliwkowski et al. 1994).  
Additionally, these non-β-cell sources do not possess the elements necessary for nutrient-
regulated secretion, and so, may only be used to fulfill the need for basally secreted 
insulin.  Like β-cells, hepatocytes possess GK and GLUT2, making them glucose 
sensitive, but these cells possess no regulated secretion pathway, and attempts to 
reengineer regulated release have relied on regulation at the level of gene transcription.  
Although success has been achieved in animal models with genetically engineered 
hepatocytes expressing insulin under transcriptional regulation by a glucose and insulin-
sensitive promoter (Thule and Liu 2000; Olson, Paveglio et al. 2003), this system cannot 
provide the acute post-meal insulin release considered necessary for glycemic 
normalization in higher animals and, eventually, humans.   
Enteroendocrine cells, exhibit many useful properties that make them appropriate 
targets for recombinant insulin expression.  Like other endocrine cells, they are capable 
of processing wild type proinsulin.  Enteroendocrine cells’ function is to secrete 
hormones called incretin which serve to potentiate insulin secretion from β-cells in the 
presence of glucose, and their regulated release parallels the secretion of insulin by β-
cells, following an oral glucose challenge (Schirra, Katschinski et al. 1996; Kieffer and 
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Habener 1999).  Thus, engineering of enteroendocrine L-cells for insulin expression 
arises as an appealing treatment for IDD in terms of dynamic release and compatibility of 
incretins and insulin in glycemic normalization.  Furthermore, studies with transgenic 
mice producing insulin from genetically engineered K cells (Cheung, Dayanandan et al. 
2000) and G cells (Lu, Sternini et al. 2005) showed that insulin-expressing 
enteroendocrine cells can provide regulation of blood glucose levels in transgenic mice.   
Previously, our lab engineered a human L-cell line to release B10-mutated insulin 
in response to nutrient administration (Tang and Sambanis 2003) and showed preferential 
transduction by adeno-associated virus for L-cells over enterocytes in a co-culture model 
(Tang and Sambanis 2004).  The B10 mutation is a naturally occurring, single point 
substitution of aspartic acid for histidine at position 10 of the B chain of insulin (Chan, 
Seino et al. 1987), which results in a superactive hormone.  In human subjects containing 
this point mutation, the physiological effect is that of hyperproinsulinemia, due to the fact 
that B10-mutated proinsulin can escape through the unregulated secretion pathway in 
contrast to native proinsulin which is almost exclusively handled by the regulated 
secretory pathway (Carroll, Hammer et al. 1988).  Nevertheless, much of the B10-
mutated proinsulin is processed via regulated secretion to become active B10-mutated 
insulin, which is notably more active than the non-mutated insulin.  Native insulin can 
form dimers and even hexamers, but only the monomeric form of insulin has 
physiological action.  B10-mutated insulin is able to form dimers, but not hexamers 
(Brange, Owens et al. 1990; Weiss, Hua et al. 1991; Liao, Tang et al. 2001).  Thus, part 
of the reason for B10 insulin’s greater activity, may be due to its higher bioavailability.  
Additionally it has been reported that B10-mutated insulin has a greater binding affinity 
to the insulin receptor than does native insulin (Schwartz, Burke et al. 1987; Brange, 
Ribel et al. 1988; Shoelson, Lu et al. 1992).  Yet another reason for the higher activity of 
B10-mutated insulin may be attributed to greater stability (Brems, Brown et al. 1992). 
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In advancing L-cell mediated insulin therapy to a tissue-engineered treatment for 
an adult mouse model for IDD, the murine L-cell line, GLUTag, was selected for this 
study, as it would represent a closer allograft model for mice and GLP-1 secretion from 
this cell line has been found similar to that of primary cell cultures (Brubaker, Schloos et 
al. 1998).  This chapter describes the genetic modification of murine GLUTag cells for 
the stable expression of human insulin and the characterization of the newly developed 
cell line, GLUTag-INS.   
3.2 Materials and Methods 
All reagents were purchased from Sigma (St Louis, MO) unless otherwise noted. 
3.2.1 Cell Culture 
GLUTag cells were obtained from the laboratory of Dr. P.L. Brubaker with the 
permission of Dr. D.J. Drucker (University of Toronto, Ontario, Canada).  The cells were 
cultured in a 37°C/5% CO2 humidified incubator in T-flasks in complete medium 
consisting of L-glutamine-free Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(Cellgro, Herndon, VA); cultures were split at a 1:5 ratio when 80% confluency was 
reached. 
3.2.2 Antibody Staining and Microscopy 
Cells were washed then fixed in 4% paraformaldehyde in phosphate buffered 
saline (PBS), permeabilized with 0.5% Triton X-100 in PBS, blocked using 10% horse 
serum in PBS before adding diluted primary antibodies (either rabbit antihuman PC1/3,  
PC2, or mouse antihuman insulin).  Cells were incubated overnight at 4°C.  The 
following day, cells were rinsed twice with PBS and diluted secondary antibody (either 
anti-rabbit or anti-mouse IgG-TRITC-conjugate) was added and incubated for 1.25 hours 
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in the dark at room temperature.  Cells were rinsed twice in PBS, coverslipped, and 
imaged by using the LSM 510 confocal microscope (Carl Zeiss Inc.).   
3.2.3 Transfection and Selection of Stable Clone 
The transgene for stable insulin expression was constructed by inserting the 
human B10 mutated insulin gene (Genentech, San Francisco, CA) into the pcDNA3.1(+) 






The expression cassette directs simultaneous expression of human insulin from 
the cytomegalovirus (CMV) promoter and neomycin resistance from the simian virus 40 
(SV40) promoter.  GLUTag cells were plated two days prior to transfection at a density 
of half-a-million cells per well of a 12-well plate.  Cells were then transfected the using 
FugeneHD (Stratagene, La Jolla, CA) according to manufacturer’s protocol at a ratio of 8 
μl FugeneHD to 2 μg DNA.  Selection of a stable clone was performed by replacing the 
medium on the day following transfection with complete medium supplemented with 200 
μg/ml Geneticin (Invitrogen).  The concentration of Geneticin was increased to 600 
μg/ml in incremental steps of 200 μg/ml over the course of two days.   Selective pressure 
was maintained for one month with medium changes every one to three days until 
colonies that were large enough to be seen with the unaided eye formed.  Individual 
colonies were transferred to wells of a 24-well plate.  Spent medium from those wells 
hB10 Insulin Rneo SV40 CMV
Figure 3.1 Elements of the plasmid used for generation of the stable 
GLUTag clone expressing human B10-mutated insulin. 
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was assayed for insulin production, the clone with the highest expression was amplified 
and used in the remainder of the studies and is henceforth referred to as GLUTag-INS. 
3.2.4 Induced Secretion Tests 
Secretion test were performed on GLUTag-INS cell monolayers in six-well tissue 
culture plates.  One million cells were seeded in each well two to four days prior to 
induced secretion tests.  On the evening prior to the secretion tests, the medium was 
changed to basal medium (DMEM with 5 mM glucose, without L-glutamine, 
supplemented with 1% FBS).  On the day of the secretion test, parallel cultures were 
briefly washed with PBS, and then subjected to three consecutive one-hour incubations in 
basal medium to stabilize basal insulin and GLP-1 secretion.  The secretion test was then 
initiated by incubating the monolayers in basal medium for two hours to establish the 
basal secretion rate.  Samples were taken, the wells were washed twice with PBS, and 
monolayers were either changed to fresh basal medium for use as non-induced controls or 
switched to basal medium supplemented with 2% (w/v) meat hydrolysate (MH) or 3-
isobutyl-1-methylxanthine (IBMX) and forskolin at 10 µM each to stimulate insulin and 
GLP-1 secretion in the induced wells.  Samples were taken at the end of the two-hour 
induction period.  This scheme is depicted in Figure 3.2. 
 
 
The time course experiment was performed in much the same way, except that 




Control MH: 0% 
MH: 2% 
2 hrs 2 hrs
Figure 3.2 Scheme used for changes in culture medium during induced secretion tests. 
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3.2.5 Assays 
Insulin and GLP-1 concentrations were determined using the human insulin and 
GLP-1 radioimmunoassay kits (RIA, Millipore, Billerica, MA) according to the 
manufacturer’s protocols. 
3.3 Results 
3.3.1 PC1/3 and PC2 Expression in GLUTag Cells 
To confirm that GLUTag cells possess the enzymes necessary to properly convert 
wild-type proinsulin to its active form, antibody staining was performed.  Figures 3.3.B 
and 3.3.C depict the staining of GLUTag cells for antibodies to PC2 and PC1/3 
respectively while Figure 3.3.A demonstrates that there was no contribution of 
background staining when cells were treated with the secondary, TRITC-conjugated, 
antibody alone.   
 
 
3.3.2 Generation of a Stable Insulin-Expressing GLUTag Clone 
In this work, an L-cell line which stably and predictably expressed insulin was 
developed by transfection and continued culture under selection pressure.  Following this 
selection period, three colonies were confirmed to produce insulin at significant levels 
B 20 µmA 20 µm
Figure 3.3 Confocal images of PC1/3 and PC2 immunofluorescence staining.  
Parental GLUTag cells stained in the absence of primary antibody (A) and with 
antibodies for PC2 (B) and PC1/3 (C). Phase contrast images have been 
overlayed to show cell outlines. 
C 20 µm 
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and displayed good growth characteristics.  The colony with the most robust insulin 
expression was used in all experiments and these cells are referred to as GLUTag-INS 
cells.  Insulin production was verified through RIA of spent medium and by 
immunofluorescent staining of engineered GLUTag-INS cells (Figure 3.4.A and Figure 
3.4.B) and parental GLUTag cells (Figure 3.4.C).  To ensure that the parental GLUTag 
cells do not express insulin, the concentrations of primary and secondary antibodies used 
to stain parental cells were 10-fold higher than those used to stain GLUTag-INS cells and 
the cells were observed under a higher magnification.  
 
 
3.3.3 Induced Secretion of Insulin and GLP-1 from GLUTag-INS Cells 
GLUTag-INS cells were evaluated in vitro using induced secretion tests to 
determine how these cells regulate the secretion of insulin and GLP-1. Nutrient 
stimulation for this experiment came in the form of 2% MH supplemented to basal 
medium, a secretagogue known to induce secretion in a number of studies using 
enteroendocrine cell lines.  Peptones, such as MH, are potent nutrient secretagogues for 
intestinal L-cells, and act not only by triggering secretion of accumulated hormone, but 
also by increasing gene transcription (Cordier-Bussat, Bernard et al. 1997; Cordier-
Bussat, Bernard et al. 1998; Tang and Sambanis 2003; Gevrey, Malapel et al. 2004; Tang 
50 µm
50 µm BA 50 µm C
Figure 3.4 Confocal images of insulin immunofluorescence staining.  
GLUTag-INS cells stained without primary antibody (A), and with an antibody for 
human insulin (B). Parental GLUTag cells stained were also stained with primary 
antibody against insulin (C).  Phase contrast images have been overlayed to show cell 
outlines. 
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and Sambanis 2004).  IBMX and forskolin, a pair frequently used as putative 
secretagogues (Dhanvantari, Izzo et al. 2001; Reimann and Gribble 2002; Reimann, 
Williams et al. 2004), were also used as a positive control, while basal secretion was 
determined through parallel tests with basal medium.  Insulin and GLP-1 induction were 
calculated by normalizing the amount of insulin and GLP-1, respectively, secreted during 
the two hours of induced secretion to the amount secreted during the two hour basal 
period.  Results are shown in Figures 3.5 and 3.6.  Secretion of insulin for all groups 
during treatment with basal medium was 424.8 ± 86.4 fmole/(well · 2 hr) (n=27 from 
three independent experiments).  Cells treated with MH and IBMX/forskolin exhibited 
220.7% ± 32.4% and 423.7% ± 47.1% induction relative to basal secretion, respectively 
(Figure 3.5).   
 
For GLP-1, the basal secretion rate was 1301.5 ± 245.1 fmole/(well · 2 hr).  GLP-
1 induction for cells exposed to MH, and IBMX/forskolin were 178.4% ± 10.3%, and 
226.0% ± 50.8% of the basal rates, respectively (Figure 3.6).  
 
Figure 3.5 Insulin release during induced secretion tests. GLUTag-INS cells were 
exposed to basal medium for two hours (open bars) followed by another two hours 
in either basal medium (control), 2% MH, or 10 µM IBMX and 10 µM forskolin 
(solid bars).  Secreted insulin is expressed as a percent of the amount secreted 
during the initial two-hour period. Mean ± SD, n=9 from three independent 




























3.3.4 Secretion Profile of Insulin from GLUTag-INS Cells 
To explore how quickly GLUTag-INS cells respond to nutrient administration, 
another secretion test was performed to better resolve the time axis, with samples taken 
every 20 minutes.  As seen in Figure 3.7, engineered GLUTag-INS cells released insulin 
in response to 2% MH in an acute manner, with a significant difference in insulin 

























Figure 3.6 GLP-1 release during induced secretion tests. GLUTag-INS cells were 
exposed to basal medium for two hours (open bars) followed by another two 
hours in either basal medium (control), 2% MH, or 10 µM IBMX and 10 µM 
Forskolin (solid bars).  Secreted GLP-1 is expressed as a percent of the amount 
secreted during the initial two-hour period. Mean ± SD, n=9 from three 




3.3.5 Proinsulin Conversion in GLUTag-INS Cells 
To evaluate the efficiency of proinsulin conversion to insulin, the concentrations 
of proinsulin and insulin accumulated in culture medium were assayed for the 
experiments of Figures 3.5 and 3.6.  Proinsulin conversion was calculated as the 
percentage of insulin secreted from GLUTag-INS cells relative to total amount of 
secreted insulin and proinsulin [(insulin*100%)/(insulin + proinsulin)].  Proinsulin 
conversion was approximately 70% when cells were exposed to basal medium.  
Incremental increases in proinsulin conversion were noted in groups treated with MH and 
IBMX/forskolin, 77.6% and 88.3% respectively (Figure 3.8).  These rises in proinsulin 
conversion (p<0.05), indicate that GLUTag-INS cells efficiently process proinsulin to 
insulin, especially in times of high demand. 































Figure 3.7 Time course of insulin secretion from GLUTag-INS cells.  Grey 
diamonds and black squares indicate insulin secreted by GLUTag-INS cells in basal 
and induction medium (2% MH), respectively.  Mean ± SD, n=9 from three 
independent experiments. *Significant difference between basal and MH groups at 




3.4.1 PC1/3 and PC2 Expression in GLUTag Cells 
In pancreatic β-cells, both PC1/3 and PC2 are needed to process proinsulin to 
insulin.  Human NCI-H716 L-cells and canine primary L-cell cultures have also been 
demonstrated to express both PC1/3 and PC2 (Damholt, Buchan et al. 1999; Tang and 
Sambanis 2004).  While in intestinal L-cells PC1/3 is responsible for processing the 
proglucagon transcript to produce glicentin, GLP-1 and GLP-2, in pancreatic alpha-cells 
proglucagon is alternately processed by PC2 to produce glucagon.  Despite the presence 
of both PC1/3 and PC2, minimal amounts of glucagon are found in intestinal L-cells 
(Damholt, Buchan et al. 1999). 
Antibody staining for both PC1/3 and PC2 was performed on GLUTag cells and 
both were found to be expressed in GLUTag cells.  The presence of both PC1/3 and PC2 
confers L-cells the ability to properly process proinsulin, as evidenced by the presence of 
immuno-reactive insulin in GLUTag-INS cells and, although not demonstrated in this 
study, it is reasonably expected that the insulin produced in these cells is also bioactive.  



















 * * 
* 
Figure 3.8 Proinsulin conversion of GLUTag-INS Cells in basal and induction 
medium.  GLUTag-INS cells were exposed to basal medium for two hours (open 
bars) followed by another two hours in either basal medium (control), 2% MH, or 10 
µM IBMX and 10 µM Forskolin (solid bars).  Proinsulin conversion was calculated 
as (insulin*100%)/(insulin + proinsulin).  Mean ± SD, n=9 from three independent 
experiments. * paired t-test with unequal variances, p < 0.05. 
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(Vague, Coste et al. 2004), a cell type that expresses equimolar amounts of insulin and C-
peptide (from proper processing of wild-type proinsulin) would offer an advantage in 
treating IDD.  
3.4.2 Generation of a Stable Insulin-Expressing GLUTag Clone 
For tissue engineering purposes, establishing a cell line which stably expresses 
insulin is desirable, such that a homogeneous population of insulin-secreting cells can be 
characterized in vitro and transplanted, as such or in a three-dimensional construct, with a 
predictable outcome.  In this work, this was achieved by transfection and continued 
culture under selection pressure.  A clone was selected through this process which stably 
expressed insulin under the control of the CMV promoter.  This clone was used in all 
subsequent experiments in this thesis that called for an insulin-expressing L-cell line, and 
is referred to as GLUTag-INS.  In preliminary studies evaluating the function of GLP-1 
secretion from GLUTag-INS cells compared to their parental GLUTag cells, it was found 
that GLP-1 secretion from GLUTag-INS cells is approximately 10-fold lower than that of 
GLUTag cells.  While this may be due to inadvertent selection of this phenotype through 
the stable clone selection process, it is very likely that the insulin secreted from the 
GLUTag-INS cells is exerting an autocrine effect on the cells, as it has recently been 
shown that GLUTag cells do express insulin receptors (Lim, Huang et al. 2008).  In this 
study it was seen that while acute exposure to insulin increased secretion of GLP-1 and 
proglucagon expression, chronic hyperinsulinemia resulted in suppression of GLP-1 
secretion and proglucagon expression.  Indeed the GLUTag-INS cell line would represent 
a model of chronic hyperinsulinemia of L-cells and based on this finding, one would 





3.4.3 Induced Secretion of Insulin and GLP-1 from GLUTag-INS Cells 
For in vitro characterization of GLUTag-INS cells, induced insulin secretion tests 
were performed, to investigate if these cells would regulate the secretion of insulin as 
they do GLP-1, despite the use of the constitutive CMV promoter to drive the 
transcription of insulin.  GLUTag cells are commonly reported to be glucose sensitive 
(Reimann and Gribble 2002; Gribble, Williams et al. 2003; Reimann, Williams et al. 
2004; Reimann, Maziarz et al. 2005; Reimann, Ward et al. 2006), but induction occurs at 
a subphysiological level of 0.5 mM, with no significant difference in secretion between 5 
mM and 25 mM glucose concentrations (Reimann and Gribble 2002).  In tests with 
GLUTag-INS cells using physiologically relevant glucose concentrations, no significant 
change in insulin secretion was measured when cells were exposed to a step change from 
5 mM to 20 mM glucose (data not shown), likely due to the hypersensitivity inherent to 
the cell line.   
With approximately 2.4 million cells per well, the level of insulin expression 
demonstrated here by GLUTag-INS cells is on par with values reported for other insulin-
secreting non-β-cells, but is about five-fold lower than that reported for β-cell lines.  The 
basal rates of insulin secretion for engineered AtT20 cells [32], engineered NCI-H716 
cells (Tang and Sambanis 2003), and GLUTag-INS cells are 60, 79, 86 fmole/(106 cells · 
hr) respectively, while the basal rate of secretion for βTC3 cells (Mukundan, Flanders et 
al. 1995) is 384 fmole/(106 cells · hr).   
As the basal medium used in this study was DMEM with 5 mM glucose and 1% 
FBS, a higher rate of basal GLP-1 secretion was expected than that seen in 
electrophysiology studies in which the basal medium is typically replaced with a nutrient-
free buffer.  For instance, the basal rate of GLP-1 secretion from GLUTag-INS cells 
measured in this study is estimated to be 7.1-fold greater than that reported by Reimann 
and Gribble for GLUTag cells in Krebs Ringer Buffer, when corrected for differences in 
culture size (Reimann and Gribble 2002).  Though there may be inherent differences in 
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the amount of GLP-1 secreted from parental GLUTag cells and GLUTag-INS, much of 
the difference in basal GLP-1 secretion rates is expected to be due to medium differences.  
This trend has also been noted for insulinoma cells:  insulin secretion rates in nutrient-
free PBS, without or with the addition of 16 mM glucose, were significantly lower 
compared to insulin secretion rates in nutrient-rich DMEM, again, without or with the 
addition of 16 mM glucose (Papas and Jarema 1998). 
The basal rate of GLP-1 secretion, however, is three-fold greater than the basal 
insulin secretion, which may explain why the induction fold was not as high for GLP-1 as 
it was for insulin (as induction folds are determined through normalization to the basal 
secretion rate).  It is interesting to note that the relative induction folds in response to 
IBMX and forskolin were 226.0% for GLP-1 and 423.7% for insulin, indicating that 
while MH caused nearly maximal secretion of GLP-1, quite a bit more insulin was 
secreted in response to IBMX and forskolin.  It has been reported that forskolin results in 
strong activation of the CMV promoter (Loser, Jennings et al. 1998) so the higher 
induction of insulin relative to GLP-1 during treatment with IBMX /forskolin  may be the 
result of additional activation of the CMV promoter controlling insulin expression in 
GLUTag-INS cells.  GLP-1 expression, controlled by the proglucagon promoter, may 
have also been affected by forskolin, as it is an activator of cAMP, which is known to 
activate the proglucagon promoter (Brubaker, Schloos et al. 1998), though the relative 
strength of each affect is unknown.  
The secretory properties of GLUTag-INS cells demonstrate that the insulin 
secretion response of this engineered cell line to various nutrient and non-nutrient 
secretagogues is in line with what has been observed for secretion of GLP-1 from 
parental GLUTag cells.  In previous studies in which an insulin-EGFP fusion protein was 
transiently expressed in human L-cells, engineered insulin-EGFP and endogenous GLP-1 
co-localized in secretory granules (Tang and Sambanis 2003).  The similarity in the 
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secretion of insulin and GLP-1 from GLUTag-INS cells suggests that co-localization of 
insulin and GLP-1 occurs in GLUTag-INS cells as well.   
3.4.4 Detailed Secretion Profile of Insulin from GLUTag-INS Cells 
To demonstrate the speed at which GLUTag-INS cells respond to nutrient 
administration, a time course experiment was performed and engineered GLUTag-INS 
cells were shown to release insulin acutely in response to 2% MH, with a significant 
difference in insulin secretion observed within the first 20 minutes.  This response is in 
agreement with observations of parental GLUTag cells, which respond rapidly to 10 mM 
L-glutamine by enhanced secretion of GLP-1 (Reimann, Williams et al. 2004). 
3.4.5 Proinsulin Conversion in GLUTag-INS Cells 
The rises in proinsulin conversion upon stimulation with medium containing 2% 
MH or 10 µM IBMX and 10 µM Forskolin indicate that GLUTag-INS cells efficiently 




DEVELOPMENT AND IN VITRO CHARACTERIZATION OF A 
TISSUE ENGINEERED PANCREATIC SUBSTITUTE BASED ON 
RECOMBINANT INTESTINAL ENDOCRINE L-CELLS 
 
A tissue engineered pancreatic substitute (TEPS) consisting of insulin-producing 
cells appropriately designed and encapsulated to support cellular function and prevent 
interaction with the host’s immune system may provide physiological blood glucose 
regulation for the treatment of insulin-dependent diabetes (IDD).  The performance of 
agarose-based constructs which contained either a single cell suspension of GLUTag-INS 
cells, a suspension of pre-aggregated GLUTag-INS spheroids, or GLUTag-INS cells on 
small intestinal submucosa (SIS), was evaluated in vitro for total cell number, weekly 
glucose consumption and insulin secretion rates (GCR and ISR), and induced insulin 
secretory function.  The three types of TEPS studied displayed similar number of cells, 
GCR, and ISR throughout four weeks of culture.  However, the TEPS which used SIS as 
a substrate for the GLUTag-INS cells, was the only TEPS that was able to retain the 
induced insulin secretory function of non-encapsulated GLUTag-INS cells.  Though 
improvements in the expression level of GLUTag-INS cells and/or the number of viable 
cells contained within the TEPS are needed for successful treatment of a murine model of 
IDD, this study has revealed a potential method for promoting proper cellular function of 






As discussed in CHAPTER 2, enteroendocrine cells, exhibit many useful 
properties that make them attractive targets for cell-therapy for IDD.  The incretins 
secreted by enteroendocrine cells are released in a tightly regulated manner that closely 
parallels the secretion of insulin by β-cells (Schirra, Katschinski et al. 1996; Kieffer and 
Habener 1999) and are compatible with insulin in glycemic normalization and 
enteroendocrine cells are able to process wild type proinsulin into mature insulin and C-
peptide.  Indeed, studies with transgenic mice, expressing insulin in enteroendocrine cells 
demonstrate that insulin-producing enteroendocrine cells can provide regulation of blood 
glucose levels in vivo (Cheung, Dayanandan et al. 2000; Lu, Sternini et al. 2005), but 
much work remains in translating enteroendocrine cell insulin therapy into a viable 
therapeutic modality for adult models of IDD and eventually humans. 
The most direct application suggested by these transgenic mice for treating IDD 
in an adult animal would be to genetically engineer the appropriate enteroendocrine cells 
in their natural environment, that is, in vivo gene therapy.  Besides significant difficulties 
inherent to delivering and stably expressing recombinant insulin in L-cells in vivo, a 
major challenge of in vivo gene therapy is in carefully titrating the treatment, so as not to 
overdose the patient with the transgene, as this might result in sustained over-production 
of insulin, an error that could be fatal.  Performing the necessary genetic modifications in 
a closely controlled manner outside of the body would greatly enhance safety.  A TEPS 
would not only provide the safety and quality control of in vitro gene therapy, but could 
additionally allow for retrieval of the construct and cells, if necessary, and for the non-
invasive monitoring of the implant by, e.g., nuclear magnetic resonance techniques 
(Constantinidis and Sambanis 1998; Stabler, Long et al. 2005; Stabler, Long et al. 2005). 
In CHAPTER 3, we modified the murine L-cell line GLUTag, to exhibit stable 
expression of human insulin such that large numbers of L-cells secreting insulin in a 
uniform manner could be cultured and used for the development of a TEPS based on such 
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cells.  This chapter describes the development and characterization of a TEPS which 
supports the function of GLUTag-INS cells and facilitates steady performance of the 
TEPS in vitro for extended periods of time.  We hypothesized that the presence of an 
extracellular matrix derived from the small intestine would be representative of the 
natural environment of L-cells and thus would improve the function of GLUTag-INS 
cells compared to TEPS which lack this support.  SIS is a cell-free extracellular matrix 
derived from the porcine intestine, and as such may represent a natural setting for 
intestinal L-cells (Badylak 2004).  It has been frequently used for the development of a 
tissue engineered intestine (Chen and Badylak 2001; Demirbilek, Kanmaz et al. 2003; 
Wang, Watanabe et al. 2003; De Ugarte, Choi et al. 2004; Wang, Watanabe et al. 2005) 
and thus may represent an intuitive reimplantation site for engineered autologous L-cells.  
Furthermore, increased cell-cell interaction within a TEPS may enhance function over 
TEPS without such interactions.  These hypotheses were tested by comparing agarose 
constructs which housed either a single cell suspension of GLUTag-INS cells, a 
suspension of pre-aggregated GLUTag-INS spheroids, or GLUTag-INS cells on small 
intestinal submucosa (SIS).  Spheroids represent a unique cellular environment and may 
influence the survival of a number of cell types (Bates, Edwards et al. 2000).  The design 
of all TEPS called for agarose encapsulation to prevent direct contact of implanted cells 
with the host during future in vivo studies with diabetic mice.  Indeed, the presence of a 
hydrogel barrier preventing direct contact with the host has proven sufficient in providing 
immunoprotection to other murine allografts in vivo (Black, Constantinidis et al. 2006).  
Agarose was selected for this study because it can be easily manipulated to encase the 
SIS and gels uniformly by cooling from 42°C to 37°C, as opposed to alginate which 
requires the addition of a divalent cation solution to induce cross-linking.  In addition, 
natural agarose of sufficient purity and low endotoxin content is available commercially 
and was used in this study. 
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4.2 Materials and Methods 
All reagents were purchased from Sigma (St Louis, MO) unless otherwise noted. 
4.2.1 Cell Culture 
GLUTag-INS cells were derived from the GLUTag cell line to stably express 
human insulin under the control of a CMV promoter (Bara and Sambanis 2008) and were 
cultured as described in CHAPTER 3. 
4.2.2 Construct Design and Fabrication 
The performance of GLUTag-INS cells, cultured within three-dimensional 
constructs, suitable for intraperitoneal implantation into a mouse, was evaluated in vitro.  
The three tissue-engineered pancreatic substitutes (TEPS) tested are depicted in Table 
4.1.  These were: (1) single cells entrapped in an inner agarose disk, which was then 
encased in a cell-free agarose disk; (2) cells pre-aggregated into spheroids and entrapped 
in an inner agarose disk, which was then encased in a cell-free agarose disk; and (3) cell- 




The total size and shape of the disks was based on the work by Stabler et al. 
(Stabler, Long et al. 2005) and was 15 mm in diameter and 2 mm in height (350 µl in 
volume).  The inner disk in (1) and (2) was 1 mm in height and 5.5 mm in diameter (100 
µl in volume).  The initial cell number in each TEPS was similar for the three designs 
tested.  To fabricate the TEPS, SIS was first seeded with GLUTag-INS cells and cultured 
prior to encapsulation.  Circular pieces of SIS were seeded by immobilized under a sterile 
cloning cylinder and incubation with a cell suspension containing 2 x 106 cells for 1 hour.  
Using gentle manipulation this process was repeated on the other side.  Cell-seeded SIS 
was then cultured for seven days in a six-well plate, suspended in 3 ml of medium until 
encapsulation.  During this culture, GLUTag-INS cells were also grown in parallel as 
monolayers for use in the other two constructs.  Spheroids of GLUTag-INS cells were 





GLUTag-INS cells pre-aggregated 
into spheroids in inner agarose disk 




GLUTag-INS single cells in inner 





GLUTag-INS cells on SIS encased 
in cell-free agarose 








Table 4.1  Tissue Engineered Pancreatic Substitutes Evaluated in this Study 
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using the conditions reported by Papas et al. (Papas, Constantinidis et al. 1993).  Briefly, 
100 ml of cell suspension, at a density of 1.2 x 106 cells/ml medium, was cultured in a 
125 ml spinner flask at 60 rpm overnight until spheroids with an average diameter of 100 
µm formed.   
The following day, the fabrication of all three TEPS was completed by 
encapsulation in 2% SeaPlaque agarose (Cambrex, East Rutherford, NJ).  The inner 
agarose disks containing either freshly trypsinized single cell suspension or a suspension 
of spheroids were formed by transferring 100 µl of the cell or spheroid agarose 
suspension to a sterile Lexan mold (McMaster-Carr, Atlanta, GA) and allowing to gel for 
5 minutes at room temperature.  Both suspensions had an overall cell density of 3 x 107 
cells/ml agarose.  Cell number per ml of settled spheroid volume was determined by 
citric acid crystal violet nuclei count and was 1.84 x 108 cells/ml spheroids.  
Encapsulation in the outer agarose layer was performed in the same manner for all 
constructs.  Briefly, the sterile Lexan mold was half-filled with agarose, the cell-
containing insert was transferred to the center of the mold, and the remaining agarose was 
added to fill the mold and allowed to gel for 5 minutes at room temperature. 
4.2.3 Viability Assessment of GLUTag-INS cells cultured on SIS 
Seven days after seeding the SIS with GLUTag-INS cells, a sample of the cell-
seeded SIS was imaged by staining with the Live/Dead Viability/Cytotoxicity Kit for 
mammalian cells (Invitrogen, Carlsbad, CA) and confocal microscopy.  This kit is 
composed of two reagents: ethidium homodimer-1 (EthD-1) and calcein AM.  EthD-1 is 
excluded by the intact cell membrane, but enters through damaged membranes and upon 
binding to nucleic acids, undergoes a 40-fold enhancement of red fluorescence.  Calcein 
AM is a virtually nonfluorescent cell-permeant molecule that is acted on by the 
ubiquitous intracellular esterase activity to produce the intensely fluorescent calcein 
(green).  The excitation/emission maxima for EthD-1 and calcein are ~495/635 nm and 
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495/515 nm respectively.   Samples were excited with a combination of 543 nm and 488 
nm lasers and long pass (560 nm cutoff) and band pass (500-550 nm cutoffs) filters were 
used to acquire the emission signals.   
4.2.4 TEPS Culture and In Vitro Evaluation 
The TEPS described above were cultured in six-well non-tissue culture-treated 
plates containing 3 ml growth medium placed on a rocking platform in a 37°C/5% CO2 
humidified incubator.  
Glucose consumption rate (GCR) and insulin secretion rate (ISR) were 
determined weekly by initially rinsing the well and TEPS twice with PBS, adding 3 ml 
fresh medium, sampling for initial metabolite concentrations, incubating for 20 to 24 
hours, and sampling again for final concentrations.  ISR and GCR measurements were 
made on the same TEPS at all time points, and parallel constructs were frozen at -80°C 
for determination of total double-stranded DNA content, which was used to estimate total 
cell number.   
Induced insulin secretion tests were also performed on all three types of TEPS. 
On the evening prior to the secretion tests, the medium was changed to basal (DMEM 
with 5 mM glucose, supplemented with 1% FBS). On the day of the secretion test, 
constructs were briefly washed with basal medium three times. During the secretion test 
all constructs were incubated in basal medium for two hours and induction medium 
(basal medium supplemented with 2% (w/v) meat hydrolysate (MH)) for another 2 hours.  
Constructs were washed with basal medium between periods and medium samples were 
reserved at the end of each period. 
4.2.5 Assays 
Samples were assayed for glucose and insulin concentration by the Trinder assay 
(Diagnostic Chemicals Limited, USA, Oxford, CT) and human insulin RIA kits 
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(Millipore, Billerica, MA) respectively, according to the manufacturer’s protocols.  To 
prepare the samples for double-stranded DNA quantification, the frozen constructs were 
thawed and dehydrated, then serially digested with proteinase K and agarase.  Double 
stranded DNA was then measured with the picoGreen kit (Invitrogen, Carlsbad, CA) 
according to manufacturer’s protocol. 
4.3 Results 
4.3.1 Viability and Total Cell Number over Time 
Cell viability was assessed by LIVE/DEAD staining for cells on SIS only prior to 
agarose encapsulation, as the thickness of the agarose prohibited any further confocal 
visualization.  After seven days of culture, GLUTag-INS cells on SIS had formed a 





Post-agarose encapsulation, the total cell number (both live and dead) in each 
TEPS was estimated based on a total DNA content, at given time points using at least 
three different constructs (Figure 4.2).  Each TEPS contained approximately the same 
number of cells, 3 x 106 cells, when encapsulated (day 0).  While the SIS-containing and 
single cell-containing TEPS showed an increase in the total cell number by day 28 
Figure 4.1 Live/Dead staining of GLUTag-INS cells cultured on SIS for 7 days 
reveals that the SIS is nearly confluent with viable cells prior to encapsulation.  
50μm 
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(p<0.05), with little increase during the first three weeks, spheroid-containing TEPS did 
not display this increase in total cell number.  SIS-containing TEPS had 3.76 ± 0.47 and 
4.46 ± 0.34 x 106 cells on days 7 and 28 respectively.  Likewise, TEPS containing single 
cell suspensions had 3.66 ± 0.45 and 5.58 ± 1.44 x 106 cells on days 7 and 28 
respectively, but TEPS containing spheroid suspensions had 4.38 ± 0.04 x 106 cells on 






Figure 4.2 Total cell number vs. time of three types of TEPS.  TEPS were frozen at 
the indicated time points and later assayed for total DNA content.  Cell numbers 
were calculated based on a standard curve of cell number vs. DNA amount 
constructed with GLUTag-INS cells on tissue culture plastic (n=3).  Points are 
shown as mean ± SD.  *There is no difference cell number among groups except on 
day 7, when the spheroid-containing group is significantly higher than the other two 
groups (p<0.05).  # Both SIS- and single cell-containing TEPS showed statistically 
significant increase in total cell number from day 7 to day 28 (p<0.05), but no 


































4.3.2 Glucose Consumption Rates 
GCR is an indicator of the overall number of metabolically active cells contained 
within the TEPS.  GCR was selected over alamarBlue® (Invitrogen, Carlsbad, CA) as 
GCR, contrary to alamarBlue®, changed minimally, if at all, upon agarose encapsulation 
of GLUTag-INS cell-seeded SIS.  GCRs of the TEPS were determined by assaying the 
glucose concentration in samples of spent medium (Figure 4.3).  As expected, the GCRs 
of the single cell-containing TEPS increased from day 7 to day 28 as the total cell number 
increased (Figure 4.2).  Though the SIS-containing TEPS also saw a rise in total cell 
number, this increase was much smaller and, as such, was not reflected in a statistical 
increase in GCR from day 7 to 28.  Also, the consistently high GCR levels of the SIS- 
and spheroid-containing groups indicate that despite low or no increase in total cell 
number, the constructs are still supporting viable cells during the month of in vitro 
culture.  Comparisons between groups on each day revealed that while the single cell-
containing group had a lower GCR than both spheroid- and SIS-containing groups on 
days 7 and 14 (p<0.05), the temporal GCR increase of the single cell-containing TEPS 
group erased this difference with the spheroid group on day 21 and with both other 




4.3.3 Insulin Secretion Rates 
As GCR provides insight into the number of metabolically active cells in the 
TEPS, insulin secretion rate (ISR) alludes to the number of secreting cells, and also 
provides insight into a key aspect of TEPS utility, that is, its ability to secrete insulin.  
There was considerable variation in the ISR profiles of the TEPS (Figure 4.4), with 
seemingly random differences appearing on throughout the course of the experiment.  On 
day 7 there were no differences among groups, but on day 14 the single cell-containing 
group had a higher ISR than the spheroid-containing group.  This difference was reversed 
on day 21 with the spheroid-group having the greater ISR.  By day 28 there was no 
difference between sheroid- and single cell-containing groups, but the SIS group was 
Figure 4.3 Glucose consumption rate (GCR) of GLUTag-INS cells in three types of 
TEPS over time. The same constructs were examined throughout the course of four 
weeks of in vitro culture after encapsulation, and glucose consumption was 
determined by assaying spent culture medium once a week (n=6). Points are shown 
as mean ± SD. SIS- and spheroid-containing groups had significantly greater GCR 
than the single cell-containing TEPS (#,* One-way ANOVA, p<0.05) on days 7 and 
14, though by day 21 the single cell-containing group showed an increase in GCR to 
match that of spheroid-containing TEPS.  By day 28 there were no differences in 
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higher than the single cell-containing group (p<0.05).  When comparing the average at all 
time points of each group, the SIS-containing group was found to have higher ISRs than 
both the single cell and spheroid groups (one-way ANOVA p<0.05), but there was no 
statistical difference between the single cell suspension and spheroid suspension groups 






Figure 4.4 Insulin secretion rate (ISR) of GLUTag-INS cells in three types of TEPS 
over time. The same constructs were examined throughout the course of four weeks 
of in vitro culture after encapsulation and the average insulin secretion rate over one 
week was determined by assaying spent culture medium in samples collected at the 
same frequency (n=6). Points show the mean ± SD. *,#,† p<0.05.  With ISR 
averaged for each group over all time points, one-way ANOVA revealed that the 
SIS-containing TEPS had a significantly greater ISR than both spheroid- and single 
cell-containing TEPS (p<0.05) but no difference was observed between the latter 
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4.3.4 Induced Insulin Secretion 
Selection of SIS as a potential substrate for an implantable TEPS arose from 
initial testing in which the basal and induced ISRs of GLUTag-INS cells grown on SIS 
were compared to those of cells grown on conventional tissue culture plastic (Table 4.2).  
For these tests, insulin secretion was measured during a two hour basal period and again 
during a two hour induced period in which the cells experienced a step up in the 
concentration of meat hydrolysate (MH) from 0% to 2%.   
 
 
Table 4.2 Comparison of Insulin Secretion Rates of GLUTag-INS Cells on Tissue 
Culture Plastic and SIS.   
 Day 2 Day 7 
 
ISR  
(µU/(106 cells · hr)) 
IF 
ISR  
(µU/(106 cells · hr)) 
IF   
  
  Basal Induced Basal Induced 
Tissue Culture 
Plastic 6.6 ± 1.19 10.0 ± 1.29 *,# 153% 11.9 ± 1.69 † 40.2 ± 2.17 *,‡ 339% 
Unencapsulated 
SIS 6.0 ± 0.60 18.6 ± 2.79 *,# 310% 7.6 ± 2.01 † 26.1 ± 1.05 *,‡ 341% 
Rates were normalized to the total number of cells measured by DNA content at each 
time point.  Values are mean ± SD, n=3. *Different than basal value on the same day for 




The main difference between the two time points (day 2 and day 7) is presumably 
cell surface density.  Though the basal and induced ISRs of GLUTag-INS cells on SIS 
are generally reduced compared to those on plastic (except for the induced rates on day 
2), it is important to note that the induction-fold (IF) is maintained.  Again, to better 
evaluate the performance of agarose-based constructs, induced insulin secretion tests 
were performed on days 7 and day 14 post encapsulation (Figure 4.5).  Induced insulin 
secretion is expressed as the percentage of insulin secreted during MH stimulation 
relative to that secreted during the basal period.  GLUTag-INS cells on SIS in agarose 
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exhibited induced release of insulin in response to nutrient stimulation on days 7 
(182.2%) and 14 (162.4%), but the GLUTag-INS cells within the other two types of 




In this study we evaluated the performance of GLUTag-INS cells within three 
types of agarose-based TEPS during four weeks of in vitro culture.  GLUTag-INS cells 
are murine L-cells which have been engineered to constitutively express human insulin 
(Bara and Sambanis 2008).  Insulin’s secretion from these cells, however, is dictated by 
Figure 4.5 Induced insulin secretion tests were performed on the same constructs on days 
7 and 14 relative to encapsulation in 2% agarose.  Constructs were incubated in basal 
medium for two hours, then the medium was changed to basal medium containing 2% 
MH for two hours.   Induced insulin secretion is expressed as the percentage of insulin 
secreted during MH stimulation relative to that secreted during the basal period (mean ± 
SD).  On days 7 and 14, the SIS-containing TEPS had a significantly higher induced 
secretion response over basal conditions (p<0.05), but the other two groups failed to 
display significant induction on both days.  Also on day 7, the SIS group was 
significantly different than both single cell and spheroid groups, but these differences 






























basal GLUTag-INS Single Cell/Agarose (n=3)
GLUTag-INS Spheroid/Agarose (n=3) GLUTag-INS SIS/Agarose (n=9)
* *
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the regulated release pathway and responds to nutrient stimulation.  A TEPS based on 
engineered L-cells may be a more likely therapeutic option for humans than delivery of 
the cells by themselves, as it accomplishes partial immune protection, localization and 
retrievability of the implant, which all contribute to superior safety and quality control.   
The use of SIS was evaluated here for the potential to improve the regulated 
secretory function of engineered L-cells, as the origin of this extracellular matrix closely 
matches the native environment of L-cells.  In addition, several studies have reported that 
the use of SIS improves the in vitro culture and function of islets (Lakey, Woods et al. 
2001; Woods, Walsh et al. 2004; Tian, Xue et al. 2005).  Though GLUTag-INS cells are 
an immortalized cell line, derived from an intestinal tumor, and may not be as peculiar to 
matrix composition as primary cells (like islets), SIS may also maintain or enhance the 
phenotype of insulin secretion from these engineered L-cells.  This is especially 
important for cells implanted in potentially unfavorable environments, such as the 
peritoneal cavity, where a drop in dissolved oxygen concentration from 0.20 mM under 
normal incubator conditions to 0.06 mM (Gross, Constantinidis et al. 2007) may cause a 
decline in insulin secretory function.  In this study, hydrated sheets of SIS were 
investigated, as this configuration may permit the polarization of the cells.  Use of 
hydrated sheets of SIS, however, required the fabrication of constructs of significantly 
larger dimensions than alginate microbeads used frequently in TEPS and islet 
encapsulation (Lim and Sun 1980).  SIS did indeed help to maintain a similar induction-
fold of insulin to that of cells grown on tissue culture plastic (Table 4.2). 
It was also observed that densely confluent monolayers of GLUTag-INS cells had 
improved secretory function over sub-confluent monolayers.  This improvement was 
reflected in increases in both basal and induced secretion rates as well as the induction 
factor (comparison of monolayers on day 2 vs. 7 in Table 4.2) and may be attributable to 
increased cell-cell interaction among GLUTag-INS cells.  As such, we hypothesized that 
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incorporating pre-aggregated spheroids into a TEPS would improve the function of the 
TEPS over similar constructs containing only single cells. 
Though several statistically significant differences were noted in the GCR and 
ISR results, these differences were nonetheless small.  Furthermore, because the 
differences among groups in the GCR data were not reflected in the ISR data, it is likely 
that the differences noted in the GCR on days 7 and 14 are due to lower oxygen 
concentrations seen by the centrally located cells within the SIS- and spheroid-containing 
TEPS.  Indeed, murine insulinoma βTC3 cells have been reported to be more oxygen 
sensitive with regard to GCR than with regard to ISR (GCR increased at oxygen 
concentrations below 25 mmHg, while the ISR decreased below 7 mmHg (Papas, Long et 
al. 1996)), and this may also be the case with GLUTag-INS cells. Again, though the 
differences in ISR among groups were small, the SIS-containing TEPS did, on average, 
slightly out-perform the single cell- and spheroid-containing TEPS.  Importantly, each 
type of construct showed no statistical change in ISR during the four weeks in culture, 
indicating a stable system which is favorable for ensuring that the TEPS does not result in 
hypoglycemia following implantation and cell proliferation in vivo.  In other systems 
using insulinoma cells, a tetracycline-responsive element has been incorporated in order 
to provide an external handle on cell growth following implantation (Efrat, Fusco-
DeMane et al. 1995).  With GLUTag-INS cells in the agarose constructs, however, this 
type of control does not appear to be needed, as ISR is stable during four weeks in 
culture.  
The induced secretion response of the three types of TEPS tested here revealed 
the most significant difference between the configurations tested.  While agarose 
encapsulation weakened the secretory response of SIS-containing TEPS compared to 
non-encapsulated SIS, possibly due to diffusional limitations of insulin and 
macromolecular constituents of MH, incorporation of SIS did allow for retention of the 
induced secretion response which was not observed in the single cell- and spheroid-
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containing TEPS.  As noted, the induction-fold of agarose-encapsulated SIS (182.2% on 
day 7) was lower than unencapsulated SIS (341% on day 7), it was however, fairly close 
to the value reported for monolayers on tissue culture plastic (218.6%) (Bara and 
Sambanis 2008).  The overall levels of basal and induced secretion of GLUTag-INS cells 
on SIS were somewhat lower than cells grown on plastic, however, and this drop was 
only further exacerbated by encapsulation in agarose.  It has been reported that βTC3 
insulinoma cells also exhibit a decline in insulin secretion upon encapsulation, although 
of a lower magnitude than that observed in this study (Mukundan, Flanders et al. 1995). 
With regard to the level of insulin secretion provided per construct, the TEPS 
described here fall short of the therapeutic threshold for a diabetic mouse.  In one study, a 
mass of genetically engineered K-cells (STC-1-14), secreting 78.6 µU/(106 cells · day) 
was implanted subcutaneously, and hyperglycemia was not reversed until about 24 days 
after implantation, indicating that some tumor growth was needed prior to reaching a 
therapeutic insulin secretion value (Zhang, Yao et al. 2008).  GLUTag-INS cells secrete a 
greater amount of insulin than the K-cells reported by Zhang et al., even at their basal rate 
of secretion, 285.6 µU/(106 cells · day) versus 78.6 µU/(106 cells · day) for STC-1-14 
cells, and as such, there is little doubt that GLUTag-INS cells would be capable of 
regulating the blood glucose levels of diabetic mice if a sufficient number of viable cells 
were implanted.  To better understand what that number would be we can look to studies 
involving the insulinoma cell line, βTC-tet.  Intraperitoneal implantation of 9 x 106 βTC-
tet cells entrapped in calcium-alginate microbeads was sufficient to reverse diabetes in 
eight-week old NOD mice within a week of implantation (Black, Constantinidis et al. 
2006).  Using the insulin secretion rates for βTC-tets reported by Simpson et al. 
(Simpson, Khokhlova et al. 2005), and assuming that the cells secrete at the stimulated 
rate for 50% of the time and the non-stimulated rate the other 50% of the time, this is the 
equivalent of a 227 mU/day.  Another estimate for the therapeutic dose of insulin for a 
diabetic mouse is 200 mU/day as provided by the subcutaneous LinBit implants (Wang 
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1991).  Thus, given the level of secretion for non-encapsulated GLUTag-INS cells 
reported for day 7 in Table II and making the same assumption that cells are secreting at 
their stimulated rate for 50% of the time and the non-stimulated rate the other 50% of the 
time, it would take 3.20 x 108 GLUTag-INS cells to treat a mouse (i.e., produce 200 mU 
insulin/day) compared to the 3 x 106 cells encapsulated in the TEPS evaluated here.  
Alternatively if the specific rate of insulin secretion of GLUTag-INS cells could be 
increased by further genetic engineering and/or manipulation of the cellular 
microenvironment then this number may be reduced significantly. 
The actual amount of insulin needed by per mouse (as with humans) may vary 
significantly depending on a number of factors including: site of delivery, metabolism, 
diet, and peripheral insulin resistance.  This underscores the importance of using cells 
which exhibit controlled release like that of islets for IDD cell therapy.  Due to the 
restrictions of allogeneic or xenogeneic transplantation, which include limited supply and 




IN VIVO EVALUATION OF TISSUE ENGINEERED PANCREATIC 
SUBSTITUTES BASED ON RECOMBINANT L-CELLS 
 
Although insulin treatments are available for diabetic patients, there are many 
disadvantages to insulin injections.  Furthermore, insulin therapy cannot prevent the 
development of severe secondary complications such as heart disease, blindness, and 
peripheral nerve damage commonly associated with diabetes.  Implantation of insulin-
secreting cells constitutes a promising alternative approach.  With the dramatically 
increasing incidence of diabetes, newer and better treatments are greatly needed. 
The objective of this aim was to implant insulin-secreting TEPS containing 
GLUTag-INS cells intraperitoneally in diabetic mice and to evaluate their function during 
and after implantation in the allogeneic host.  GLUTag-INS cells characterized in 
CHAPTER 3 were encapsulated in two different geometries—the SIS/agarose based 
TEPS described in CHAPTER 4 and calcium-alginate microbeads.  Both types of 
constructs are referred to as TEPS and were implanted intraperitoneally in diabetic mice.  
In vivo efficacy of GLUTag-INS containing TEPS was compared to controls, fabricated 
in the same manner but containing either no cells or parental GLUTag cells (negative 
controls) or insulin-secreting mouse insulinoma cells (positive control).  Non-fasting 
blood glucose and weight were determined throughout the duration of the experiment and 
plasma insulin levels, liver glycogen content, and histology of the agarose constructs 
were assessed post-mortem. 
5.1 Introduction 
The goal of the work in this chapter was to evaluate the in vivo performance of 
TEPS based on genetically modified GLUTag-INS cells.  Rodent models are the most 
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commonly used in vivo test bed for diabetes research due to cost, ethical considerations, 
and ease of use.  Here, we use the STZ mouse model, in which STZ is administered to 
chemically induce the onset of IDD.  As introduced in CHAPTER 2, another commonly 
used model for IDD, the NOD mouse, may have autoimmunity to β-cells and/or the 
insulin produced by β-cells. Due to this complication, the NOD model may not be 
appropriate for the proof-of-principle experiments proposed in this chapter. 
A number of implantation sites have been used in the past to implant insulin-
secreting cells, either alone or as part of a bioartificial pancreas.  These include the 
intraperitoneal (Stabler, Long et al. 2005; Black, Constantinidis et al. 2006), 
subcutaneous (Tatarkiewicz, Hollister-Lock et al. 1999), subrenal (Carlsson, Palm et al. 
2000; Han, Lee et al. 2007), intrasplenic (Soria, Roche et al. 2000), and intrahepatic 
(Matsumoto, Okitsu et al. 2005) implantation sites.  Alternatively, intravascular devices 
are connected to the vasculature directly and perfused by the host’s blood.  For a 
diffusional device of large dimensions such as ours, the intraperitoneal space was the 
location of choice. 
When assessing a TEPS, the physiological effects typically evaluated are weight 
gain or loss, blood glucose levels, and often blood insulin and HbA(1)c concentrations 
(Salvay, Rives et al. 2008; Zhao, Amiel et al. 2008).  Because insulin plays such a major 
role in maintaining normal metabolism and physiology, there are a number of other 
possible assessments that may be performed to gain a better understanding of what is 
happening in vivo including liver glycogen storage (Ito, Bujo et al. 2005) and lipid profile 
(Olson, Paveglio et al. 2003).  Additionally evaluating the implant itself after 
explantation for insulin secretion, and immunohistochemical analysis are very important 
in determining the overall performance of a TEPS in vivo. 
In this chapter two geometries of TEPS were implanted intraperitoneally in 
diabetic mice: calcium-alginate microbeads and an agarose disk construct containing cell-
seeded SIS.  Non-fasting blood glucose concentrations and body weights were 
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determined throughout the duration of the experiment for mice implanted with both types 
of constructs, while mice implanted with the agarose disks were also tested for plasma 
insulin levels, liver glycogen content, and histology of the explanted constructs post-
mortem. 
5.2 Materials and Methods 
All methods were approved by the Georgia Institute of Technology Institutional 
Animal Care and Use Committee. 
5.2.1 Fabrication of TEPS 
 SIS-containing TEPS of disk geometry were fabricated as described in 
CHAPTER 4.  Briefly, pieces of SIS (14 mm in diameter) were seeded with cells and 
cultured for one week prior to encapsulation in 2% SeaPlaque agarose.  To encapsulate, 
the sterile Lexan molds were half-filled with warm alginate, the cell-containing or cell-
free SIS was positioned centrally within the mold and the remaining agarose was added 
to fill the mold.  The final dimensions of the disk-shaped constructs were 15 mm in 
diameter and 2 mm in height (or 350 µl in volume). 
 TEPS comprised of calcium-alginate microbeads were fabricated as described by 
Simpson et al. (Simpson, Stabler et al. 2004).  Cell monolayers were harvested with 
trypsin-EDTA and suspended in 2% sodium alginate (high mannuronic acid content 
(LVM) alginate; FMC BioPolymer, Drammen, Normay) at a density of 3 x 107 cells/ml.  
Beads with a diameter of ~500 µm were generated using an electrostatic bead generator 
(Nisco, Basel, Switzerland) and alginate was crosslinked in a bath of 100 mM CaCl2. 
 Prior to implantation, insulin secretion from both types of TEPS was evaluated by 
overnight incubation in culture medium, and insulin content in the medium samples was 
assayed by RIA (Millipore, Billerica, MA). 
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5.2.2 Induction of Diabetes  
Diabetes was induced in normal, C57BL/6J mice by giving a single injection of 
200 mg/kg STZ while mice were under isoflurane anesthesia. Anesthesia was induced by 
isoflurane at a dose of 5% delivered in 1 liter/min oxygen by a precision vaporizer (via 
inhalation in a chamber with a scavenger).  Anesthesia was maintained with isoflurane at 
a dose of 1.2 to 1.5% in 300 ml/min oxygen, delivered through a nose cone with 
scavenger.  Depth of anesthesia was verified by lack of pedal withdrawal reflex and slow 
irregular respirations.  Mice that withdrew the foot after toe was pinched were given 
more isoflurane in the smallest increment the vaporizer allowed.  After an adequate plane 
of anesthesia was confirmed, the STZ was administered by intraperitoneal injection.  
Following at least 24 hours, the diabetic state was determined by blood glucose 
monitoring with the TrueTrack Smart System® (Home Diagnostics, Inc, Ft Lauderdale, 
FL) using blood collected at the tail tip site. Onset typically occurred three days after 
injection and was defined as those mice with two consecutive non-fasting blood glucose 
levels of more than 250 mg/dl.   
5.2.3 Implantation of Artificial Pancreases 
The experimental groups for each experiment (alginate microbead or SIS/agarose 
disk TEPS implantation) are described in Table 5.1. To prepare the mice for implantation 
surgery, isoflurane anesthesia was induced and maintained as described earlier, via 
inhalation in a chamber and through a nose cone respectively.  After an adequate plane of 
anesthesia was confirmed, hair was removed from the abdomen and the skin prepared 
with successive applications of chlorhexadine and alcohol. Mice were then covered with 
a sterile drape with a fenestration over the abdomen.   
For the disk-shaped artificial pancreases, a midline abdominal incision was made 
through the skin and muscle with surgical scissors and the implant was positioned in the 
peritoneal cavity on top of the viscera.  The muscle layer was closed with 6-0 absorbable 
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suture in a simple interrupted pattern.  For artificial pancreases of bead geometry, 
implantation was accomplished by a small incision through the skin and injection with a 
16 gauge needle through the muscle layer.  In each type of surgery, the skin was closed 
with mouse-sized wound clips.  Immediately following surgery, mice were kept warm 
with a heat lamp and an injection of buprenorphine (0.05 mg/kg,) was administered as 
soon as the mice recovered from the isoflurane anesthesia.   
 




(Cells Seeded) Group 
Healthy None + Control 
Diabetic 
βTC-tet cells
None - Control GLUTag cells
GLUTag-INS cells Test 
 
5.2.4 Monitoring Body Weight and Blood Glucose 
Mice were observed daily and body weights were recorded.  When appropriate, 
blood glucose was also assessed by collection of a drop of blood at the tip of the tail and 
rapid measurement with a TrueTrack Smart System® hand-held glucose monitor and 
disposable testing strips (Home Diagnostics, Inc). 
5.2.5 Plasma Insulin Levels 
After determination of graft failure or at a specified time after implantation, mice 
were euthanized.  Immediately following euthanization by CO2 inhalation, approximately 
1 mL of blood was obtained by cardiac puncture.  Blood was allowed to clot at room 
temperature, and then centrifuged at 1600 g at 4°C to isolate the plasma.  Plasma was 
frozen at -80°C until assayed by Human Ultra-sensitive RIA (Millipore). 
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5.2.6 Retrieval of Artificial Pancreases 
 Upon termination and immediately following blood draw by cardiac puncture, the 
constructs were retrieved.  Retrieval was initiated by injection of Hank’s balanced saline 
solution (HBSS) to loosen the constructs from surrounding tissues then a midline 
abdominal incision through skin and muscle was made with surgical scissors.  The disk 
constructs were located visually and gently lifted out of the peritoneal cavity using a 
sterile spoon.  Microbeads were retrieved by aspiration of the injected saline solution and 
peritoneal fluids containing the microbeads.  Approximately 0.2 ml of beads were able to 
be retrieved. 
5.2.7 Insulin Secretion from Implants 
Explanted constructs were placed in complete culture medium and returned to 
incubator conditions overnight to assess the insulin secretion capability post implantation.  
Times were noted when each construct was placed into culture and upon sampling the 
following day.  Insulin concentration was determined using the Human RIA (Millipore). 
5.2.8 Live/Dead Staining and Confocal Microscopy 
All images were taken on the LSM 510 confocal microscope (Carl Zeiss Inc.).  
The Live/Dead viability/cytotoxicity kit (Molecular Probes) was used to stain samples for 
viability assessment on SIS as described in CHAPTER 4.   
5.2.9 Immunohistochemistry of Constructs  
 Following overnight incubation, the remaining constructs were fixed in 30% 
sucrose overnight, snap frozen in OCT, and stored at -80°C until 7 µm thick sections 
were sampled using the cryostat.  Slides with frozen sections were stored at -80°C until 
used for immunohistochemistry (IHC). 
To prepare the samples for IHC, frozen slides were brought to room temperature, 
fixed in cold acetone for five minutes, washed twice in PBS, blocked in 2% serum for 20 
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minutes, and blocked with Avidin D for 15 minutes.  Then the diluted primary antibodies 
were applied to the sections.  To determine if explanted constructs contained cells that 
contained insulin, insulin staining with a monoclonal anti-insulin antibody (product 
number I 2018, Sigma) was used at a 1:100 dilution.  On other samples, the immune 
response was investigated using a CD68 antibody for macrophages (product number 
ab53444, Abcam, Cambridge, MA) and a neutrophil antibody (product number ab2557, 
Abcam) at dilutions of 1:200 and 1:100 respectively.  Sections were incubated with 
primary antibody overnight at 4°C in a humid chamber.  The following day, slides were 
washed twice with PBS, incubated with the appropriate biotinylated secondary antibody 
for 30 minutes.  To reveal the staining, slides were treated with the ABC-alkaline 
phosphatase kit.   
The procedure for use of the ABC-alkaline phosphatase kit was as follows.  Slides 
were blotted and washed two times in PBS to remove excess antibody and a working 
solution of ABC-alkaline phosphatase complex (Vector #AK-5000) was applied to the 
samples for one hour at room temperature.  Slides were again blotted and rinsed in PBS 
prior to incubation with 100 mM tris (pH 8.2) for five minutes.  The alkaline substrate 
solution (Vector Red #SK-5100) containing levamisole (Vector #SP-5000) was then 
applied to the sections and incubated in the dark for 30 minutes.  The reaction was 
stopped by blotting and rinsing twice in PBS.  Finally slides were counterstained with 
hematoxylin, coverslipped and imaged. 
5.2.10 Liver Glycogen Storage  
Liver tissue was also harvested at time of euthanization.  Livers were formalin-
fixed and paraffin-embedded.  Sections, 5 µm thick, were sampled from select livers and 
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glycogen content of the fixed tissue was qualitatively determined by Periodic Acid-Schiff 
(PAS) staining.  The periodic acid selectively oxidizes the glucose residues, creating 
aldehydes that then react with the Schiff reagent to create a purple-magenta color.  
Briefly, the sections were deparaffinized and rehydrated in distilled water, rinsed once 
more in distilled water, then immersed in 0.5% periodic acid for five minutes.  Slides 
were washed three times in distilled water and covered in Schiff’s solution for 15 
minutes.  Slides then were treated with 0.55% potassium metabisulfate two times for one 
minute each to remove excess stain and washed in running tap water for 10 minutes to 
develop the color.  Following PAS staining, slides were counterstained with hematoxylin, 
rinsed with tap water, and dehydrated by immersion in 95% and 100% alcohol twice 
each.  Finally slides underwent two changes of xlene and were coverslipped with 
synthetic resin. 
5.3 Results 
5.3.1 Monitoring Body Weight and Blood Glucose 
5.3.1.1 Implantation of Constructs of Disk Geometry 
 Beginning several days prior to STZ administration mice were weighed daily and 
their blood glucose level was sampled regularly.  Body weight and blood glucose as a 
function of time for mice implanted with disk-shaped constructs have been plotted for 
each group of mice in Figures 5.1 and 5.2 respectively on the following pages.  Day 0 is 
the day of implantation and both day 0 and the day on which STZ was administered are 
demarked with a vertical black line. 
 As expected, all mice becoming diabetic following STZ injection started losing 
weight at this point while the healthy control group, which received only buffer, 
continued to gain weight.  It is also no surprise that following this major surgery a slight, 
but noticeable drop in body weights of all groups was observed.  Upon recovery in the 
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subsequent four days the non-diabetic mice gained weight (p<0.01), but no differences in 
weight were noted for any other group, though the weight gain between days 1 and 4 of 
the βTC-tet group nearly gained significance (p=0.053).   
 Prior to STZ administration, all mice maintained their blood glucose 
concentrations within a narrow range of healthy, non-diabetic values (130 to 200 mg/dl).  
While this range was maintained for the healthy control group throughout the duration of 
this experiment, the mice receiving STZ saw a steep increase in blood glucose levels 
within two to four days following injection and then maintained hyperglycemic blood 
glucose levels above 250 mg/dl.  Mice treated with insulin-secreting βTC-tet cells did 
have lowered blood glucose on day 2 post implantation compared to the pre-implantation 
value (paired t-test, p<0.05).   A decline in blood glucose was also noted for GLUTag and 
sham (cell-free) treated negative controls on days 2 and 4 respectively (p<0.05).  Though 
these drops were statistically significant, they were still well within the diabetic range of 
blood glucose values, and as these are measured during the non-fasting state, some 
variation is to be expected.
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Figure 5.1 Body weights of mice implanted with disk-shaped constructs.  STZ was administered on day -5 to all groups 
except the healthy positive control (injected with buffer only). Constructs were implanted on day 0.  The condition of the 
mouse and the type of cells seeded on the SIS embedded within the agarose is indicated in parenthesis within the legend.  












-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5
















Positive Control (BTC-tet) Positive Control (healthy mouse) Negative Control (GLUTag)





Figure 5.2 Blood Glucose levels in mice implanted with disk-shaped constructs.  STZ was administered on day -5 to all 
groups except the healthy positive control (injected with buffer only). Constructs were implanted on day 0.  The type of cells 
seeded on the SIS embedded within the agarose is indicated in parenthesis within the key.  * Blood glucose of the healthy 
group was significantly lower than all other groups (One-way ANOVA, p<0.005).  @ βTC-tet and GLUTag groups had lower 
blood glucose values on day 2 compared to day -1 (paired t-test, p<0.05).  # The cell-free negative control had lower blood 
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5.3.1.2 Implantation of Constructs of Bead Geometry 
 Body weight and blood glucose concentrations of mice implanted with calcium-
alginate microbeads have been plotted for each group of mice as a function of time in 
Figures 5.3 and 5.4 respectively on the subsequent pages.  Day 0 is the day of 
implantation and both day 0 and the day on which STZ was administered are demarked 
with a vertical black line. 
 As expected, all mice becoming diabetic following STZ injection started losing 
weight at this point while the healthy control group, which received only buffer, 
continued to gain weight.  In contrast to the implantation of disk-shaped constructs, mice 
undergoing microbead implantation did not display the drop in body weight following 
implantation, presumably because the surgery in this case is minor, resulting in an easier 
recovery for the mice with sooner return to normal food ingestion. 
Prior to STZ administration, all mice maintained their blood glucose 
concentrations within a narrow range of healthy, non-diabetic values (130 to 200 mg/dl).  
While this range was maintained for the healthy control group throughout the duration of 
this experiment, the mice receiving STZ saw a steep increase in blood glucose levels 
within two to three days following injection to a hyperglycemic range (above 250 mg/dl).  
While mice in the negative control group maintained this level of hyperglycemia, mice 
treated with insulin-secreting βTC-tet cells saw a quick decline in blood glucose levels 
and both mice became hypoglycemic by day 2 or 3.  Though one mouse treated with 
GLUTag-INS cell saw a decline in blood glucose to below the diabetic threshold, the 
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Figure 5.3 Body weights of mice implanted with microbead constructs.  STZ was administered on day -4 to all groups but 
the healthy positive control (injected with buffer only) and constructs were implanted on day 0.  The condition of the 
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Figure 5.4 Blood glucose levels in mice implanted with microbead constructs.  STZ was administered on 
day -4 to all groups but the healthy positive control and constructs were implanted on day 0.  The condition 
of the mouse and the type of cells encapsulated within the alginate microbeads is indicated in parenthesis 
within the legend. 
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 The assessments of implant function described in sections 5.4.2 to 5.4.8 were 
conducted only on mice receiving constructs of the disk geometry. 
5.3.2 Plasma Insulin Levels 
 Despite the lack of effect of insulin-expressing cell-containing TEPS of disk 
geometry on body weight or blood glucose levels, human insulin was detected (using the 
human ultrasensitive RIA kit) in the plasma of GLUTag-INS cell treated mice (5.1 ± 1.8 
µU/ml, Figure 5.5 B).  This level was significantly higher than the level detected in sham 
treated mice (p<0.05).  The level measured from healthy mice in Figure 5.5 B is 
apparently due to the cross-reactivity of murine insulin with the human RIA.  As this 
level is similar to the level detected in sham-treated mice, the cross-reactivity of murine 
insulin on the human ultrasensitive kit is quite low.  It is also interesting to note that the 
mice treated with murine βTC-tet cells had significantly elevated plasma levels of murine 
insulin (detected using the rat RIA) compared to healthy mice and GLUTag- and sham-
treated diabetic mice (p<0.05) (Figure 5.5A).  
 
Figure 5.5 Blood plasma levels of murine (A) and human (B) insulin in mice implanted 
with disk-shaped constructs.  The normal value of healthy mice detected with each kit is 
the far left bar (open) in each graph while the far right bar (grey) in each graph is the 
value detected for sham treated diabetic mice.  Insulin concentration (µU/ml) is shown 












































5.3.3 Insulin Secretion from Implants 
 In order to quantify the insulin secretory function of the constructs both pre-
implantation and post-explantation, constructs were incubated with complete culture 
medium overnight and the accumulated insulin was assayed.  These values are compared 
in Table 5.2.  While insulin was detected under both circumstances, the amount measured 
following explantation was markedly lower than the pre-implantation values for both 
GLUTag-INS and βTC-tet-containing constructs.  
 
Table 5.2 Insulin Secretion from Implants Pre-implantation and Post-explantation. 
 GLUTag-INS βTC-tet 
Pre-Implant 216.7 ± 13.6 μU/(construct·day) 65.2 ± 11.9 mU/construct/day 
Post-explant 56.2 ± 7.9 μU/(construct·day) 2.0 ± 1.8 mU/construct/day 
% of pre-
implantation 
25.9 ± 3.4% 2.8 ± 2.3% 
 
 80 
5.3.4 Construct Retrieval and Inspection 
 Visual inspection of the constructs following retrieval after only four days of 
being implanted revealed many structural flaws in the encapsulating agarose layer as seen 
for a selection of the constructs in Figure 5.6.  The breakages did not appear to be 
correlated to whether or not the constructs contained cells or were cell-free.  The pink 
observed in some explanted constructs was the result of incubation in phenol red-




Figure 5.6 Appearance of disk-shaped constructs post-explantation. 
17.9 mm 
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5.3.5 Live/Dead Staining and Confocal Microscopy 
Though the Live/Dead staining of retrieved βTC-tet-, GLUTag-, and GLUTag-
INS-containing constructs (Figures 5.7.C -E) revealed large amounts of green 
fluorescence, which was not present in non-implanted cell-free SIS (Figure 5.7.A), a 
similarly implanted cell-free construct (Figure 5.7.B) also displayed this green staining.  
Thus the viable cells detected with this method could very easily have originated from the 
host and implanted cells are not distinguishable from host cells using this assay. 
 
5.3.6 Immunohistochemistry of Constructs for Host Immune Response 
 The influence of the host’s immune response toward the implants was 
qualitatively investigated using immunohistochemistry.  Antibody staining against 
macrophages (Figure 5.8) and neutrophils (Figure 5.9) revealed that a strong reaction 
occurred against GLUTag-INS-containing constructs and to a lesser degree cell-free 




Non-implanted Cell-free SIS 





Because neutrophil staining was positive after four days of implantation, thus 
indicating a chronic inflammation, samples of non-implanted constructs and agarose were 
evaluated for endotoxin content using the QCL-1000 Endpoint Chromogenic LAL Assay 
(Lonza).  All samples containing agarose, even in the absence of SIS and cells, were 




Implanted GLUTag-INS Construct Implanted Cell-free Construct 
Figure 5.8 Macrophage staining of constructs using a CD68 antibody.  Antibody revealed 






Implanted GLUTag-INS Construct Implanted Cell-free Construct
Figure 5.9 Neutrophil staining of constructs using a NIMP-R14 antibody. Antibody revealed 
with ABC-Alkaline phosphatase and Vector Red substrate and counterstained with 
hematoxylin.
Non-implanted GLUTag-INS Construct 
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5.3.7 Insulin Immunohistochemistry of Constructs 
 Insulin immunohistochemistry was attempted on non-implanted GLUTag-INS 
constructs (positive control), non-implanted cell-free constructs (negative control), and 
implanted GLUTag-INS and cell-free constructs (tests) (Figure 5.10).  While weak 
staining was observed for non-implanted GLUTag-INS constructs and not on non-
implanted cell-free constructs, more staining was seen unexpectedly on both implanted 
samples.  In an attempt to get a sharper image of the insulin antibody staining by 
fluorescent detection, a different secondary antibody was used which was TRITC 
conjugated.  Despite the change in the secondary antibody and detection system, the same 
results were obtained, indicating that the primary antibody used had unexpected cross-
reactivity to an epitope of a host cell.  As insulin expression from the constructs post-
explantation had been demonstrated by secretion assay, staining was not repeated using 
another primary anti-insulin antibody. 
 
Non-implanted GLUTagINS Implanted GLUTagINS 
Non-implanted Cell-free Implanted Cell-free 
Figure 5.10 Insulin staining of constructs using a monoclonal insulin antibody. 
Antibody revealed with ABC-Alkaline phosphatase and Vector Red substrate 
and counterstained with hematoxylin. 
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5.3.8 Liver Glycogen Storage 
 Another measure of how the implants may have affected the mice’s metabolism 
was the amount of glycogen stored within liver cells.  Qualitatively examined here by 
PAS staining of formalin-fixed livers, it was seen that healthy, non-diabetic mice showed 
the greatest amount of stored glycogen (Figure 5.11 A).  Sham treated diabetic mice and 
diabetic mice treated with GLUTag-INS cells showed similar levels of glycogen storage 
(Figure 5.11 B and D).  A slightly lower level of staining was noted for GLUTag cell-
treated mice (Figure 5.11 E).  Though βTC-tet-treated mice (Figure 5.11 C) showed more 
staining than the other diabetic groups, it was nonetheless lower than the amount seen in 
healthy mice.  As with the staining seen in healthy controls, localized deep staining was 






Figure 5.11 Liver glycogen storage of mice implanted with disk-shaped constructs.  
Sections, 5 µm thick, of formalin-fixed paraffin-embedded livers were stained by 
PAS and counterstained with hematoxylin.  Magenta staining indicates stored 
glycogen.  Liver sections were obtained from healthy mice (A), sham-treated 
diabetic mice (B), and diabetic mice treated with βTC-tet cells (C), GLUTag-INS 
cells (D), or GLUTag cells (E). 
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5.4 Discussion 
The implantation of the GLUTag-INS cell-containing disk-shaped SIS constructs 
was not predicted to restore normoglycemia due to the subtherapeutic level of insulin 
secretion measured from these constructs, as discussed in CHAPTER 4.  A significantly 
higher dose of insulin was measured from the disk-shaped SIS TEPS containing βTC-tet 
insulinomas in vitro, though it was only about 30% of a therapeutic dose.  If that level of 
insulin secretion was maintained in vivo it may have affected the blood glucose levels of 
diabetic mice, though restoration of normoglycemia would be unlikely with only 30% of 
the therapeutic dose.  Indeed, neither GLUTag-INS- nor βTC-tet-containing disk-shaped 
constructs lowered blood glucose levels to normoglycemic levels, though a small drop in 
blood glucose was noted for the βTC-tet constructs on day 2.  TEPS of the microbead 
geometry containing βTC-tet cells, however, have been shown in several previous studies 
to correct hyperglycemia of diabetic mice (Black, Constantinidis et al. 2006), and it is no 
surprise that we saw a quick reversion to normoglycemia following implantation of βTC-
tet microbeads and, in the absence of growth control by tetracycline, the subsequent 
decline of blood glucose to hypoglycemic levels.  The volume of microbeads containing 
GLUTag-INS cells implanted in this study, however, was not sufficient to restore 
normoglycemia.  Though more beads could have been implanted, the volume predicted to 
be necessary to treat diabetes in a mouse (12.4 ml), is quite large.  To avoid this large 
implantation volume, an increase in cell density and/or further improvements in the 
insulin expression level of L-cells would be required. 
Retrieved implants retained some insulin secretion capacity following the four 
day implantation, but the magnitude of the decline in insulin secretory function for the 
agarose/SIS constructs was surprising.  GLUTag-INS and βTC-tet containing constructs 
retained just 25.9% and 2.8% respectively of their pre-implantation insulin secretion 
levels.  There are several possible contributing factors for this rapid decline: (1) breakage 
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of the encapsulating agarose layer around the SIS, (2) immune response to the exposed 
cells and/or agarose, and (3) diffusion-limited supply of oxygen and nutrients. 
The structural integrity of the SIS disk constructs following a relatively short time 
in vivo was significantly less than predicted by previous studies implanting agarose only 
disks of similar dimensions and composition (Stabler, Long et al. 2005).  Though 
structural failure may have contributed to the rapid decline in insulin secretory function 
from the disk constructs, it cannot be solely blamed, as an SIS-free agarose construct 
containing GLUTag-INS cells, which did not experience any structural damage following 
four days of implantation, saw a similar drop in insulin secretion as the broken SIS-
containing controls. 
Leukocytes such as neutrophils and macrophages bind to implanted tissue 
engineered devices through surface-absorbed opsonins to result in attachment and 
activation, secretion of reactive oxygen intermediates, release of proteolytic enzymes and 
phagocytosis of the implant (Babensee, Anderson et al. 1998).  Following any surgical 
procedure, it would be expected that some macrophages and neutrophils would be 
recruited to the site.  The degree to which the excised agarose/SIS TEPS stained positive 
for macrophages and neutrophils four days after implantation, however was quite 
significant.  Though CD68 is classically used as a macrophage marker, though there is 
evidence that other cells, such as fibroblasts may also express CD68 (Gottfried, Kunz-
Schughart et al. 2008).  Regardless of the specific origin of the CD68 staining, since it 
was not present in the non-implanted controls, it is still indicative of a host reaction.  
Though breakage of the agarose and exposure of the implanted cells directly to the host’s 
immune cells probably exacerbated the immune reaction, it is likely that similar results 
would have been obtained regardless of breakage, as the endotoxin test of the agarose 
tested positive (>0.5 EU/ml).  Indeed, the implanted cell-free constructs displayed an 
inflammation response.  Neutrophils are the hallmark of acute inflammation, serving to 
remove foreign materials and bacteria from the injury site.  They normally occur within 
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an hour of injury and with a short lifespan of about 24 hours give way to macrophages 
and eventually fibroblasts.  If the inflammatory stimulus persists, however, chronic 
inflammation occurs (Babensee, Anderson et al. 1998).  Given that the construct stained 
positive for neutrophils as far out as four days indicates a chronic inflammatory reaction.  
This inflammatory response certainly could have been detrimental to the cells contained 
within the TEPS, as non-specific lysis of encapsulated cells may be mediated by 
lysosomal enzymes or reactive oxygen or nitrogen intermediates released by activated 
leukocytes. 
Other factors may have also had an impact on in vivo function, particularly a 
decrease in available oxygen and nutrients.  Intraperitoneal dissolved oxygen 
concentration drops considerably to 0.06 mM compared to the level of 0.20 mM 
experienced under normal incubator conditions (Gross, Constantinidis et al. 2007).  A 
drop to this level may certainly have an effect on insulin secretory function, as has been 
observed in insulinoma cells (Papas, Long et al. 1996). 
Though normoglycemia was not achieved by implantation of the disk constructs, 
human insulin was measurable in GLUTag-INS-implanted mice, and mouse insulin 
levels were elevated for all cell-treated mice, relative to sham-treated diabetic mice.  For 
the mice implanted with constructs containing either βTC-tet or GLUTag-INS cells, a 
straight-forward explanation is available for the presence of murine or human insulin, 
respectively, in serum samples, as these constructs demonstrated insulin secretion both 
before implantation and after retrieval.  Interestingly, though the plasma insulin detected 
in diabetic mice implanted with βTC-tet-containing constructs was significantly higher 
than the plasma insulin of healthy controls, blood glucose concentrations were not 
returned to normal values.  A possible explanation for this rests with the physiological 
changes that take place during extended periods of hyperglycemia, chiefly the increase in 
peripheral insulin resistance.  It has been reported that in STZ-induced diabetes, 
hyprerglycemia leads to progressive insulin resistance of the peripheral tissue (Ordonez, 
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Moreno et al. 2007).  Some of the changes that occur following hyperglycemia are an 
impairment of GLUT4 translocation in skeletal muscle (Dombrowski, Roy et al. 1998) 
and an inhibition in glycogen synthase in adipocytes (Parker, Taylor et al. 2004).  Thus, 
glycemic regulation is not a state function.  Whereas one level of insulin results in a 
certain blood glucose level prior to the onset of diabetes, a different amount of insulin 
may be required to achieve the same blood glucose level after the onset of diabetes.  This 
means that curing diabetes by a cell substitute is further complicated by the path that 
glycemic regulation has taken.  Therefore in the study with transgenic mice which 
produced insulin from intestinal K cells (Cheung, Dayanandan et al. 2000), the amount of 
insulin needed to avoid the onset of diabetes might have been significantly lower than the 
level that would have been needed if the same animals had experienced hyperglycemia 
and developed peripheral insulin resistance. 
The reason for elevated serum murine insulin in the GLUTag cell-treated mice 
relative to sham-treated negative controls may be due to the delivery of GLP-1 from the 
construct which is known to potentiate the secretion of insulin from β-cells in the 
presence of glucose (Drucker 2001).  The known actions of GLP-1 also include restoring 
glucose competence in glucose resistant β-cells, stimulating insulin gene expression and 
biosynthesis, and to acting as a growth factor by promoting cell proliferation, survival, 
and neogenesis (Buteau 2008).  Since this is a model for IDD and the β-cells were 
specifically ablated by STZ, the precise action of GLP-1 is a little more complicated.  It is 
possible that (1) some percentage of pancreatic β-cells evaded harm from STZ 
administration and GLP-1 served to potentiate insulin secretion, (2) damaged (but not 
destroyed) β-cells were able to recover some function following GLP-1 action, (3) GLP-1 
worked to increase β-cell mass by regeneration, or (4) a combination of these 
mechanisms was at work in mice implanted with GLP-1-secreting cells.  Indeed, GLP-1 
has been shown to attenuate the destruction of β-cells by STZ (Li, Hansotia et al. 2003; 
Pospisilik, Martin et al. 2003). 
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Since the constructs were implanted intraperitoneally, and the insulin secreted by 
them would be picked up by the vasculature of the mesentery, which empties into the 
portal system, direct effects on the liver may have been observed even in the absence of 
correction of blood glucose levels.  In healthy subjects, the liver is a major consumer of 
secreted insulin, with 50% of insulin (which empties directly from the pancreas into the 
portal vein of the liver) being used by the liver during the first pass (McPhee and Ganong 
2006).  Insulin’s effect in the liver is primarily to promote fuel storage by way of 
stimulating glycogen synthesis and inhibiting gluconeogenesis and glycogenolysis.   
Liver glycogen content for GLUTag-INS-treated mice and sham-treated diabetic 
controls was similar, but GLUTag-treated mice appeared to have less glycogen storage 
than the aforementioned groups.  This was unexpected as we did see some elevation in 
plasma insulin in response to GLUTag-cell implantation, presumably due to GLP-1 
action, but may be explained because GLUTag cells process proglucagon to release 
glucagon as well as GLP-1 (Drucker, Lee et al. 1992).  Glucagon and insulin are 
antagonistic hormones, with glucagon promoting glycogenolysis and glucose production 
from the liver.  We did observe in CHAPTER 3 that the level of GLP-1 secreted from 
GLUTag-INS cells is about 10-fold lower than that secreted from parental GLUTag cells.  
Since GLP-1 and glucagon are derived from the same prohormone, it is likely that 
glucagon would also be reduced in recombinant GLUTag-INS cells compared to the 
parental GLUTag cell line, though glucagon secretion from GLUTag-INS cells has not 
been characterized.  Thus, the relative levels of glucagon secretion from GLUTag-INS 
cells compared to GLUTag cells, combined with the secretion of insulin by GLUTag-INS 
cells, may explain why a drop in glycogen storage was observed in GLUTag-implanted 
mice relative to GLUTag-INS-implanted mice. 
Though not entirely comparable, βTC-tet-treated mice displayed liver glycogen 
staining much like healthy controls with localized deep staining present in many cells, a 
trait not evident in the other groups.  This is to be expected given the relatively high level 
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of murine plasma insulin detected in βTC-tet-treated mice.  Though the differences 
observed in liver glycogen storage among mice of various groups are interesting, the 
results would be much more convincing if a quantitative liver glycogen assay had been 
performed rather than the qualitative PAS staining and had the livers not been formalin-
fixed, this sort of a quantitative assay would have been conducted.  The repeatability of 
these results among all mice of each group also remains to be examined. 
In summary, even though reversion of hyperglycemia was not expected or 
achieved from the agarose/SIS TEPS containing GLUTag-INS cells, a great deal about 
the in vivo performance of this type of construct was still obtained during this study.  
Though insulin secretory function of the constructs was diminished to a fraction of the 
pre-implantation value, insulin was secreted from constructs containing GLUTag-INS 
and βTC-tet cells in vivo and was detectible in the plasma samples taken four days after 
implantation.  Intraperitoneal implantation of the agarose/SIS constructs exposed the 
predisposition towards rupture at the agarose-SIS interface.  A significant inflammatory 
response was noted in the implanted constructs and was likely due to the presence of 
endotoxin from the agarose.  Slight qualitative differences in the liver glycogen storage 
were noted for experimental groups of agarose/SIS TEPS treated mice, but these results 
should be further characterized with a quantitative assay for liver glycogen. 
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CHAPTER 6 




Though considered a treatable chronic disease, insulin-dependent diabetes (IDD) 
remains a serious public health issue.  Because of patient compliance and the delay 
inherent to sampling blood glucose and administering insulin, exogenous insulin 
injections cannot provide the tight physiological control of blood glucose necessary to 
prevent the onset of secondary complications.  Cell-based treatments which sense 
changes in surrounding blood glucose concentration and respond rapidly to secrete 
insulin in a physiological manner potentially represent a cure for IDD.  The use of 
recombinant β-cell surrogates as a cell-based treatment for IDD has been investigated for 
several years, but many of the potentially autologous cell sources have significant 
drawbacks.  Enteroendocrine cells have recently emerged as very promising potential 
surrogate β-cells.  However, translating enteroendocrine cell therapy for IDD to a viable 
therapy for human use is not without its challenges.  In this thesis, we have contributed to 
the field by studying the insulin secretory function of recombinant L-cells and evaluating 
their potential for use in an implantable tissue engineered pancreatic substitute both in 
vitro and in vivo.   
To accomplish the goals set forth in this thesis, three aims were planned which 
progressed from the engineering L-cells at the cellular level, to then evaluating the 
performance of the cells within three-dimensional tissue engineered constructs in vitro, 
and finally determining their performance upon implantation into a diabetic mouse 
model. 
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The results of the first aim, discussed in CHAPTER 3 describe how we modified 
the murine GLUTag cell line by stable transfection with an expression plasmid which 
coded for human B10-mutated insulin driven from the CMV promoter and for neomycin 
resistance from the SV40 promoter.  Following selection through the antibiotic 
resistance, we established a clonal cell line, called GLUTag-INS.  This line was then 
characterized for insulin and GLP-1 secretion under normal culture conditions using both 
basal and inducing medium conditions.  It was found that GLUTag-INS cells did co-
secrete human insulin and murine GLP-1 in response to both putative and nutrient cues.  
Importantly, GLUTag-INS cells responded quickly to the step up in nutrient 
concentration by action of the regulated secretion pathway, without the delay found when 
relying on transcriptional regulation, as is necessary in non-endocrine cell types. 
Proinsulin was also efficiently converted to mature insulin through the action of the 
endogenous endoproteases PC1/3 and PC2 (Bara and Sambanis 2008). 
The second aim of this thesis described in CHAPTER 4, evaluated three potential 
configurations of an implantable agarose disk construct in terms of their ability to support 
cellular growth and metabolic and secretory functions of the encapsulated GLUTag-INS 
cells.  The three constructs evaluated in this work were agarose constructs which housed 
either a single cell suspension of GLUTag-INS cells, a suspension of pre-aggregated 
GLUTag-INS spheroids, or GLUTag-INS cells on SIS.  It was learned that despite 
similarities in overall cellular growth and basal insulin secretion and glucose 
consumption rates, SIS-containing TEPS performed better than single cell or spheroid-
containing TEPS in terms of induced insulin secretory function.  This key aspect to 
regulated insulin secretion was not evident in the two constructs which did not contain 
the SIS substrate (Bara and Sambanis 2008, submitted to Biotechnology and 
Bioengineering). 
Finally, in the third aim of this work, SIS-containing agarose constructs and 
alginate microbead constructs were implanted into the peritoneal cavity of STZ-diabetic 
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mice revealed interesting findings and uncovered several short-comings of the TEPS.  As 
the developed TEPS based on agarose-encapsulated SIS, did not secrete a sufficient level 
of insulin to treat a diabetic mouse, blood glucose lowering and weight gain were not 
observed in GLUTag-INS treated mice.  Likewise, GLUTag-INS-containing alginate 
beads did not display a blood glucose lowering effect.  The volume of beads implanted in 
these preliminary experiments was only 1 ml whereas the volume predicted to restore 
normoglycemia is 12.4 ml.  It was seen that the SIS-containing agarose was much more 
structurally unstable than predicted based on previous implantation of agarose only 
constructs of similar dimensions.  Breakage of the encapsulating agarose layer, however 
was just one of the factors identified that may have played a role in the decline of insulin 
secretory function measured from the constructs post-explantation compared to the pre-
implantation level.  Other culprits may have included limitations in oxygen and other 
nutrients to cells housed in the constructs and an inflammatory response that included 
both macrophages and neutrophils.  Importantly though, we were able to detect human 
insulin in the plasma samples of GLUTag-INS treated mice (which was not detected in 
sham-treated controls or healthy, non-diabetic mice) even after four days of implantation, 
when insulin secretory function of the TEPS was already quite low relative to initial 
levels.  Qualitative liver glycogen storage images also suggested some benefit in 
metabolic health of the GLUTag-INS and especially the βTC-tet treated mice despite the 
subtherapeutic level of insulin delivered. 
In summary, this thesis took the developed a tissue engineered pancreatic 
substitute based on recombinant intestinal L-cells from engineering and characterization 
of the L-cells themselves, to in vitro characterization, and carried it all the way through to 




6.2 Future Directions 
6.2.1 Increasing Insulin Expression 
In order to reach therapeutic levels of insulin secretion from a TEPS based on 
recombinant L-cells, the specific cellular insulin secretion rate and/or the total number of 
viable cells delivered in vivo would need to be improved.  Increasing insulin expression 
from GLUTag-INS cells by additional gene delivery is one possibility (Clark, Quaade et 
al. 1997).  As unforeseen changes may occur during additional rounds of stable clone 
selection, using another stable selection method is probably not the best option.  This may 
have been why insulin-producing STC-1 K cells (Ramshur, Rull et al. 2002), which 
underwent two sequential rounds of stable clone selection, exhibited considerably 
different cell physiology than was expected based on the behavior of non-engineered 
cells in vivo.  To avoid this complication, viral methods of gene delivery, such as 
lentiviral or retroviral vectors which provide stable gene expression, may be employed to 
facilitate additional gene expression in GLUTag-INS cells.  Alternatively, another 
engineered L-cell source could be generated de novo starting with parental GLUTag 
cells, an L-cell enriched population of STC-1 cells, or even human NCI-H716 cells using 
the same viral vectors just mentioned. 
6.2.2 Increasing Cell Loading of TEPS 
Another option for increasing the level of insulin secretion from a TEPS based on 
recombinant L-cells is to deliver more of the GLUTag-INS cells and to improve the 
expected viability of the cells following implantation.  With the tissue engineering 
approach, the number of cells that may be implanted is more limited due to space 
restrictions in vivo and the contribution of the biomaterial.  Many preliminary studies in 
the area of cell-transplantation for IDD can bypass this limitation by implantation of cells 
alone, usually subrenally or subcutaneously, so as to localize the implanted cell mass.  
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Indeed, this was the approach used by Zhang et al. to evaluate recombinant K cells  
(STC-1-14) in vivo (Zhang, Yao et al. 2008).  Though the initial amount of insulin 
secreted by the implanted cells, 78.6 µU/(106 cells · day), was not sufficient to reverse 
hypoglycemia, the cell mass expanded in vivo and 24 days after implantation, the mice 
were able to restore blood glucose levels to normal values.  As the GLUTag-INS cells 
developed in this thesis secreted more insulin than STC-1-14 cells, it is reasonable to 
believe that a similar study using these cells would also demonstrate the ability to treat an 
IDD mouse model. 
Many benefits may be seen, however, by incorporating the recombinant L-cells 
into a tissue engineered device, as such scaling up of the macroconstruct containing 
hydrated sheets of SIS described in this thesis is not a viable option, considering the 
limits imposed by what are considered to be implantable dimensions, especially given the 
breakage obtained at the current dimensions.  TEPS consisting of alginate or agarose 
microbeads can easily be scaled up while retaining very good mechanical properties.  It 
may also be possible to incorporate specific adhesive ligands or extracellular matrix 
proteins into the basic alginate or agarose microbeads.  Given the work presented in this 
thesis, addition of solubilized SIS to the microbeads may be beneficial in enhancing 
insulin secretory function of GLUTag-INS cells (Lakey, Woods et al. 2001).  
Alternatively individual adhesive ligands or extracellular matrix components could be 
incorporated in the alginate or agarose gels (Rowley, Madlambayan et al. 1999; 
Connelly, Garcia et al. 2007).  We have not compared the function of GLUTag-INS cells 
on the gel preparations of SIS, however, and cannot assume that there is any specific 
ligand in the hydrated sheets of SIS that supports the function of GLUTag-INS cells.  It 
may well be that general adhesion to a semi-rigid surface is the mechanism by which 
induced insulin secretion was improved in GLUTag-INS cells on SIS compared to 
suspensions in agarose, as an even stronger induction response was observed on non-
coated tissue culture plastic. 
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6.2.3 Genetic Engineering of Primary L-cells 
A very important direction that this line of research should one day explore is the 
genetic engineering of intestinal stem cells which give rise to primary L-cells.  Recently, 
the discovery of the intestinal stem cell marker, Lgr5, a transmembrane protein with a 
large extracellular domain for ligand binding, has opened doors to a number of important 
studies that were not possible just a couple of years ago  (Barker, van Es et al. 2007).  
With the Lgr5 marker now available, it will be possible to visualize, isolate, and 
genetically modify stem cells of the adult intestine. 
Obviously, a significant challenge to overcome remains the ability to establish 
primary cultures of murine L-cells, which are well defined and have good viability in 
vitro.  As epithelial cells may require the presence of mesenchymal cells to survive and 
proliferate in vitro (Sanderson, Ezzell et al. 1996), isolation of stem cell/ mesenchymal 
cell aggregates, termed organoids rather than individual stem cells, may facilitate 
successful in vitro culture and successful transplantation (Choi and Vacanti 1997).   
A likely implantation site for recombinant intestinal stem cells is back to the 
intestine itself and an interesting model has been studied as a site for heterotopic auxiliary 
liver is the isolated vascularized small intestinal segment (Berishvili, Liponava et al. 
2003; Joseph, Berishvili et al. 2004).  In this model, a segment of the small intestine 
along with its vascular supply is removed from the gastrointestinal tract, the ends of the 
intestine from which it was cut are anastomosed to restore flow of the intestine, and the 
isolated segment is denuded to remove the mucosa and the ends are ligated shut to create 
a sac.  This model has recently been used by Avansino et al. in rats (Avansino, Chen et al. 
2006) and mice (Avansino, Chen et al. 2006) to study the transplantation of intestinal 
organoids containing stem cells in vivo.  It would be very interesting to see if this 
technique could be used to transplant recombinant intestinal stem cells, which drive the 
expression of insulin from the L-cell specific proglucagon promoter, as in vivo 
transplantation may facilitate longer study than in vitro culture. 
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In vivo engineering of the murine intestinal epithelium is another potential 
direction.  A segment of the intestine with the mucosa intact, could be targeted by either 
the isolated vascularized segment just described or simply by temporary clamping of the 
segment (Sandberg, Lau et al. 1994).  Then, a gene vector capable of chromosomal 
integration would be delivered to drive the expression of human insulin from the 
proglucagon promoter.  Genetic modification of intestinal stem cells has also been 
proposed by use of an inducible Cre recombinase, integrated into the Lgr5 locus, such 
that Cre knock-ins can be directly inserted into intestinal stem cells (van der Flier and 
Clevers 2008) so long as the inserted gene did not interfere with the critical properties of 
the stem cells. 
 
This is an exciting era in the advancement of intestinal stem cell gene therapy for 
the treatment of a number of disorders and diseases.  Though much remains to be learned 
prior to human application, the elegance of using enteroendocrine cells for developing a 
potentially autologous cell therapy for IDD will certainly drive the progress in this area. 
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APPENDIX A 
PRIMARY COLONIC CRYPT CULTURES 
 
A.1 Introduction 
Evaluating the efficiency of gene transfer to primary L-cells and more importantly 
to their progenitors—intestinal stem cells, would be a significant step toward the 
advancement of insulin gene therapy in somatic enteroendocrine cells.  L-cells represent 
less than 1% of the population of intestinal epithelial cells; thus, obtaining a pure 
population of enteroendocrine L-cells would be very challenging.  L-cells are primarily 
located at the base of structures called crypts of the distal small intestine (ileum) and the 
colon.  The small intestine has numerous villi projecting into the lumen around the 
mouths of the crypts whereas the colon only has crypts.  Colonic crypts are also larger 
than crypts found in the ileum and do not contain Paneth cells (Bach, Renehan et al. 
2000; Kaeffer 2002); as such, only crypts from the colon were isolated.  This Appendix 
describes the initial work toward a proof-of-concept experiment to isolate and transduce 
murine colonic crypts which are rich in intestinal stem cells.    The studies described here 
evaluated the viability of various preparations of primary murine colonic crypts over the 
course of several days of in vitro culture. 
A.2 Materials and Methods 
A.2.1 Colonic Crypt Isolation 
All procedures were conducted in accordance with the recommendations of the 
Georgia Tech Institutional Animals Care and Use Committee.  Male 10-to-12-week-old 
BALB/c mice were obtained from Taconic Laboratories (Germantown, N.Y.) and 
sacrificed by CO2 asphyxiation.  Immediately after confirmation of death, a portion of the 
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colon was removed just distal to the illeal-cecal valve and a modification of the method 
described by Perreault and Beaulieu (Perreault and Beaulieu 1998) was initiated.  
Complete culture medium for primary cultures was Dulbeco’s Modified Eagle 
Medium supplemented with 2.5% FBS, 1% non-essential amino acids, 10 ng/ml 
Epithelial Growth Factor, 10 ng/ml Leukemia Inhibitor Factor, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 25 µg/ml gentamycin.  The digestion solutions used were 
culture medium supplemented with (1) Matrisperse (a non-enzymatic solution used to 
depolymerize Matrigel Matrix) at a 50:50 ratio with complete medium or (2) 150 U/ml 
collagenase XIa and 40 µg/ml dispase A. 
The intestine was flushed with cold Hanks’ balanced salt solution (HBSS) to 
remove luminal contents followed by flushes containing 0.4 M N-acetyl-L-cysteine to 
remove mucous. The intestine was then cut open longitudinally and into 0.5-cm 
fragments. These were incubated with digestion solution at 22°C for solution (1) or 37°C 
for solution (2) on an orbital shaker platform for 3 hours or until crypts were seen to be 
released from the tissue.  Upon completion of tissue digestion 5 ml additional culture 
medium was added and the centrifuge tubes were rapidly inverted 10 times to disperse 
the crypts. The suspension was allowed to settle for 1 minute and then 5 ml of the 
solution was collected by aspiration.  This washing step was repeated five times for a 
total volume of crypt-containing media of 30 ml. This suspension was passed through a 
nylon mesh filter with a pore size of 180 µm to separate crypts from larger cell 
aggregates and then immediately plated on wells coated with either type I collagen or 
Matrigel.  Crypts were separated from single cells by an additional sedimentation step in 
which the culture was incubated for 10 minutes and the supernatant was then replaced 




A.2.2 Viability Assays 
Viability was assessed at various time points using the Trypan blue dye exclusion 
method and automated counting using the ViCell device or LIVE/DEAD staining as per 
the manufacturer’s protocol and fluorescent confocal microscopy. 
A.3 Results 
Prior to digestion of the tissue, Live/Dead staining showed that the colonic tissue 
was highly viable without any appreciable red staining (Figure A.2).  The dark areas of 
the images in the honeycomb-like lattice reveal where the crypts protrude or recede from 
the plane of view of the slice taken with confocal imaging. 
Dissection
HBSS & NALC 
Washes
Digestion & Filtering 
through 180 µm mesh 




Figure A.1 Overall scheme of the isolation protocol used to 




The protocol described for crypt isolation yielded cultures which were rich in cell 
clusters that had the structural characteristics of crypts, as seen in Figure A.3.  The three 
dimensional cone shapes of the crypts are evident from the darker long edges of the 
clusters where many cells are stacked on one another to make the wall of the crypt 




Figure A.2 Live/Dead stain of freshly isolated whole colonic tissue reveals highly 
viable intestinal tissue, with virtually no red staining detected using the multi-photon 
confocal microscope with dual channel settings for FITC and Rhodamine. 
Figure A.3 Representative image of isolated murine colonic crypts 
isolated by Matrisperse digestion.  The cone-shaped structure of the 
crypts is apparent in many of the cell clusters (10X). 
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Viability was also assessed on isolated crypt cultures by Live/Dead staining and is 
shown in Figure A.4.  Although the Live/Dead staining performed just three hours after 
colonic crypt isolation revealed a mostly viable crypt structure (Figure A.4), by 24 hours 
after isolation, no viable staining was observed (not shown).   Given this rapid decline, 
follow up studies were performed to compare the time course of viability of cultures 
isolated by the two different digestion solutions, or cultured under different conditions 




To quantify the difference in culture viabilities following digestion, dead cells 
were stained blue by Trypan blue and percent viability was determined using an 
automated counting device.  Viabilities were assessed for two to three days, by which 
point all cultures were generally less than 30% viable.  The effect of supplementing the 
culture medium with 2.5% FBS was also evaluated.  Though the results presented here 
are very preliminary (n=1), some features are of note.  With the exception of the isolation 
shown in Figure A.5, cultures generally retained good viability (greater than 60%) up to 
Figure A.4 Live/Dead staining of a colonic crypt cell preparation, plated on tissue 
culture plastic, three hours after the isolation (4X).  Panels A and B were taken on 
the same area of interest, using different filter blocks of the fluorescent microscope 
for FITC and rhodamine respectively. 
A B 
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24 hours after isolation.  Beyond this point, however, the viability dropped steeply.  In 
Figure A.5, crypts isolated by the non-enzymatic Matrisperse digestion solution and 
plated on Matrigel-coated wells, displayed very poor viabilities even at early time points.  


















Figure A.5 Viability time course for crypts isoloated by the Matrisperse digestion 
solution and plated on Matrigel-coated wells.  Cells were trypsinized and viability 
assessed by Trypan blue dye exclusion. 
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Significantly greater viabilities were seen for the cultures isolated by the 
enzymatic digestion solution containing collagenase and dispase (Figure A.6), though 
because this was a much more efficient solution at matrix disintegration than the 
Matrisperse solution, it is not clear if the viable cells are from the epithelium or from the 
underlying mucosa.  Given this uncertainty, the more gentle Matrisperse digestion was 
the preferred method.  In the case of the enzymatic digestion, however, it appeared that 
the presence of 2.5% serum was actually somewhat detrimental to the cells. 
When comparing the viability of cultures obtained by Matrisperse digestion, crypt 
cells plated on collagen (Figure A.7) had appreciably higher viabilities than those plated 
on Matrigel (Figure A.5).  The choice of extracellular matrix, however, does not lend any 


















Figure A.6 Viability time course for crypts isolated by the collagenaese and dispase 
digestion solution and plated on Matrigel-coated wells.  Cells were trypsinized and 




These preliminary experiments verified that organ cultures of adult intestinal 
tissue rapidly display necrosis and degeneration of the epithelium, with cultures in vitro 
being maintained for a maximum of twelve to twenty-four hours (Quaroni 1989; Kaeffer 
2002).   
The purity and/or viability of the cultures we obtained was not suitable for 
evaluating the possibility of gene transfer to the epithelium by viral transduction or 
chemical transfection, because of the long times necessary to visualize expression of the 
reporter protein.  On a shorter time scale, however, it may be possible for one to evaluate 
binding of viruses to the cell surface of primary cultures, perhaps with co-localization of 
cell-specific antibodies to determine which cells are targeted by various viruses.   
Factors that may have affected the viability of crypt cultures include (1) the length 
of procurement time; (2) the temperature at which isolation was performed; (3) the 
digestion solution used; (4) the coating used on the culture surface; and (5) culture 















Figure A.7 Viability time course for crypts isolated by the Matrisperse digestion 
solution and plated on collagen-coated wells.  Cells were trypsinized and viability 
assessed by Trypan blue dye exclusion. 
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Matrisperse digestion solution was better at obtaining cultures with greater content of 
crypts and that collagen-coated surfaces enhanced viability compared to Matrigel-coated 
surfaces.  The results pertaining to culture medium supplementation with FBS, were 
unconvincing, and this supplement as well as a number of other possible supplements 
including growth factors should be further evaluated to determine an optimal 
maintenance medium.  The isolation process could likely be improved by optimization of 
these factors. 
Viability may also be superior when isolating fetal or neonatal tissue (Fukamachi 
1992; Ramsanahie, Duxbury et al. 2003).  Additionally leaving some of the surrounding 
mesenchymal tissue intact and isolating organoids may also significantly improve the 
longevity of the primary cultures (Sanderson, Ezzell et al. 1996).   
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APPENDIX B 
GENE DELIVERY TO MURINE L-CELL LINES 
 
Introduction 
Previous work from our laboratory established methods to transiently transfect 
and preferentially transduce human NCI-H716 L-cells (Tang and Sambanis 2004), but in 
moving towards a murine L-cell line for developing a TEPS, initial studies needed to be 
performed on how to transfer genes of interest to the murine enteroendocrine GLUTag 
and STC-1 cell lines.  As non-endocrine NIH-3T3 fibroblasts would be used as a negative 
control for the proglucagon promoter to be tested in APPENDIX C, these cells were also 
included in this study.  In this study, the gene transferred to each cell type was the 
commonly used reporter gene, green fluorescent protein (GFP).  Chemical transfections 
were performed using two commercially available reagents and transduction by an 
adenoviral vector was also performed. 
Materials and Methods 
Transfection of Cell Lines 
GLUTag, STC-1, and NIH-3T3 cells were transfected with the chemical 
transfection reagents FugeneHD (Roche, Indianapolis, IN) and lipofectamine (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions, at varying concentrations of 
the transfection reagent in relation to amount of plasmid DNA.  These protocols involved 
first the formation of a complex between the plasmid DNA and transfection reagent, then 
the dilution in serum-free medium, and delivery of the complex to cell monolayers that 
have been incubated with antibiotic-free medium overnight, to reduce the toxic effects of 
the antibiotic that may occur during the transfection procedure.  The amount of plasmid 
DNA was held constant at 2 µg and the ratios of FugeneHD to DNA tested in this study 
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were: 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2 (µl FugeneHD : µg DNA).  For Lipofectamine the 
concentrations of reagent tested were 1X, 2X, 3X, and 4X. 
Transduction of Cell Lines 
Gene transfer for enteroendocrine cells was also evaluated by transduction with 
adenoviral vectors.  The vectors used in this study, AdTrack and AdG3Fur/AdCMV-GFP 
were all generously supplied by the Thulé lab and contained expression cassettes for 
GFP.  Transduction was performed simply by addition of the virus to the culture medium 
of the cell monolayers at a dose of viral particles to cells (multiplicity of infection, 
M.O.I.) of 1.  Expression of the fluorescent protein was evaluated 24-48 hours after 
transduction by fluorescence microscopy using a GFP filter block.  
Results and Discussion 
Transfection of Cell Lines 
As evident from the fluorescent micrographs (Figure B.1), FugeneHD was the 
better reagent for the transfection of the GLUTag cell line.  The transfection efficiency 
was further characterized by flow cytometry and the 7:2 ratio yielded approximately 20% 
transfection efficiency.  This was improved to 36% transfection by quadrupling the total 
amount of transfection complex used per well.  STC-1 L-cells, however, were not 
transfected efficiently by either FugeneHD or Lipofectamine (Figure B.2).  NIH-3T3 
cells were transfected most efficiently with Lipofectamine with the 2x concentration of 





Figure B.2 STC-1 cells transfected with FugeneHD (left panel) or Lipofectamine 
(right panel). For FugeneHD, various ratios of µl transfection reagent to µg DNA 
were tested, while with Lipofectamine, various concentrations of the transfection 











Figure B.1 GLUTag cells transfected with FugeneHD (left panel) or Lipofectamine 
(right panel).  For FugeneHD, various ratios of µl transfection reagent to µg DNA were 







Transduction of Cell Lines 
As expected based on previous studies with rat intestinal epithelial cells (Cheng, 
Kolls et al. 1997), adenoviral vectors strongly and efficiently transduced the 
enteroendocrine cell lines STC-1 (Figure B.4) and GLUTag (Figure B.5).  This approach 
to gene delivery may be less useful when targeting L-cells in mixed populations such as 
primary cultures, as they would not show preferential gene transfer to enteroendocrine 








Figure B.3 NIH-3T3 cells transfected with FugeneHD (left panel) or Lipofectamine 
(right panel). For FugeneHD, various ratios of µl transfection reagent to µg DNA were 









Though the methods of gene delivery investigated here typically yield only 
transient gene expression, as expression usually ceases after two to four days since 
episomal DNA is degraded by the cells.  They are nonetheless very useful for conducting 
short-term studies.  Transfection may also be adapted for stable expression by 
incorporation of an antibiotic resistance gene and delivery of the linearized plasmid to 
promote chromosomal integration.  This approach to stable transfection was used in 
CHAPTER 3 to produce the GLUTag-INS cell line and the results obtained in the 
preliminary transfection studies described here, contributed to the success of that 
approach. 
Figure B.4 STC-1 cells transduced with AdTrack (24 hours post transduction) 




L-CELL SPECIFIC GENE EXPRESSION 
 
C.1 Introduction 
In moving to a more physiologically relevant system, as with transduction of 
primary intestinal L-cells either in vitro following isolation or in vivo, appropriate care 
must be taken in targeting L-cells for insulin expression.  Given the complex nature of the 
intestinal epithelium and the multitude of surrounding non-L-cells, high specificity of 
transduction and/or expression is required to ensure that the insulin transgene is not 
expressed errantly by non-intended cells.  Driving expression of insulin from an L-cell 
specific promoter would provide this specificity of gene therapy at the level of gene 
expression. 
To obtain nutrient-regulated secretion of insulin in L-cells, reliance upon the 
cells’ native regulated secretion pathway is crucial.  It has been shown previously that 
insulin can be co-secreted with GLP-1, in genetically modified L-cells.  Glucagon, GLP-
1, GLP-2, and glicentin are all derived from preproglucagon and are expressed in a 
tissue-specific manner at the level of post-translational modification (Mojsov, Heinrich et 
al. 1986).  GLP-1 is only produced by L-cells and is derived from the proglucagon gene.  
Therefore, we could hedge the expression of insulin off of the natural production of GLP-
1 by inserting the insulin gene downstream of the proglucagon promoter.  The goal of this 
study was to determine if the cloned murine proglucagon promoter would drive the cell-
type specific expression of a transgene at a level that would be appropriate for insulin 
expression.  The homogeneous GLUTag enteroendocrine cell line was used as a positive 
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control for expression while the non-enteroendocrine cell lines, NIH-3T3 (fibroblasts) 
and T84 (enterocytes) were used as negative controls for testing specificity of the vectors 
developed for this study. 
C.2 Materials and Methods 
C.2.1 Proglucagon Promoter Description and Primer Design 
The mouse glucagon sequence was found by searching for “glucagon” on Entrez 
Gene (www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene), NCBI's database for gene-
specific information.  From this search, the record for Mus Musculus (mouse) was 
selected.  The information about the glucagon (Gcg) gene was provided from Mouse 
Genome Informatics (MGI) and the full sequence (including flanking regions) was 
accessible from the MGI website.  The “AF382209 Mus musculus glucagon gene 












Figure C.1 Sequence of the glucagon gene promoter region used for PCR cloning. 
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The section in larger size font matches the mouse proglucagon promoter sequence 
reported by Cordier-Bussat et al. (Cordier-Bussat, Morel et al. 1995).  The sequences in 
bold are called E-boxes which have the consensus motif CANNTG and are known to 
interact with transcription factors characterized by a helix-loop-helix DNA-binding motif.  
These E-boxes are found in the promoter elements G1 and G4.  In addition there are two 
other promoter elements G2 and G3 and a cAMP responsive element (CRE) also found in 
the proglucagon promoter.  These are shown schematically in Figure C.2. 
 
 
Figure C.2 Schematic of the 5’ flanking enhancer and promoter elements of the  
proglucagon promoter from -50 bp to -350 bp (Cordier-Bussat, Morel et al. 1995). 
 
 
In order not to diminish the strength or specificity of the promoter the full length 
of the proglucagon promoter including all of the elements just described was selected for 
cloning.  As such, primers to initiate the PCR cloning were designed to match the 
upstream and downstream sequences of the proglucagon promoter shown above.  Primers 
were selected based on the recommendations of Invitrogen’s custom primer design 
application, Oligo PerfectTM, and these included the insertion of appropriate restriction 
endonuclease recognition sequences on the 5’ ends of both forward and reverse primers.  
In addition to the online tools, the primers were checked against the sequence using the 
Amplify program.  The sequences and properties of the primers are described in Table 
C.1.    
CRE G3 G2 
G4 G1 
E3   IS  E2        E1 
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Table C.1 Primer Design for the PCR Cloning of the Mouse Proglucagon Promoter 








Bgl II site 39 93% 67% 
Rev gctagctagcgtagacagaggga
gtccccttgggaa 
Nhe I site 36 93% 68% 
 
  
C.2.2 PCR Cloning of the Proglucagon Promoter 
To obtain the full length mouse proglucagon promoter (mPGp), polymerase chain 
reaction (PCR) was employed and the mouse genomic DNA library served as template 
DNA.  The PCR reaction was set up by the addition of 1 µl template mouse genomic 
DNA (Cat No. 69239-3, Novagen, San Diego, CA), 5 µl of 5 µM forward and 5 µl of 5 
µM reverse primers (Invitrogen, Carlsbad, CA), 5 µl of 2 mM dNTP mix (Promega, 
Madison, WI), and 5 µl 10X Vent polymerase buffer (New England Biolabs, NEB, 
Ipswich, MA) to a PCR tube and adjusting the total volume to 50 µl by addition of 
DNase- and RNase-free water.  The reaction mixture was covered with two drops of 
mineral oil to prevent evaporation and the tube was placed in the thermocycler set to the 
80°C hot start setting to prevent nonspecific annealing.  Then 1U Vent polymerase was 
added to the reaction and mixed with the pipette tip.  The thermocycler was programmed 
with the following temperature steps, repeated for a total of 35 cycles: (1) 30 s at 94°C, 
(2) 30 s at 65°C, and (3) 90 s at 72°C.  This PCR reaction was run in seven different 50 
µl reactions, and the products were pooled and purified using the Wizard PCR prep kit 
(Promega).  The final concentration of eluted mouse proglucagon promoter (mPGp) was 
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15.5 ng/µl as approximated by intensity comparison to the DNA standard following gel 
electrophoresis of a 1 µl sample. 
C.2.3 Gene Construct Generation 
The expression plasmid selected for initial testing of the proglucagon promoter 
was one containing the luciferase gene and it is depicted in Figure C.3.  The luciferase 
system is very sensitive (less than 10-20 moles of luciferase can be detected under ideal 
conditions) and the half life of luciferase in mammalian cells is three hours, so the 
product does not accumulate, allowing changes in promoter activity to be detected.  It 
was for these reasons the pRLnull vector was selected.   
 
 
Erroneously the restriction sites chosen for cloning the proglucagon promoter into 
the pRLnull vector were Bgl II and Nhe I, this resulted in the release of the fragment 
containing the MCS, intron, and T7 promoter.  This was done in an effort to ensure no 
contribution of expression due to the presence of the T7 promoter because of a 
misunderstanding about its function.  The T7 promoter is included only for optional in 
Figure C.3 Vector map of the pRLnull expression plasmid (Promega).   
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vitro transcription studies in E.-coli, yet as there is no ribosome binding site or Shine 
Delgarno sequence to initiate translation, the mRNA will not be translated into proteins. 
Following PCR cloning of the promoter fragment, the murine proglucagon 
promoter (mPGp) was digested with the restriction endonucleases Bgl II and Nhe I 
(NEB) in NEB buffer 2 at 37°C for 12 to 16 hours to ensure digestion at the difficult to 
digest ends of the linear DNA.  Similarly, the pRLnull vector backbone (Promega) was 
digested for 2 hours with Bgl II and Nhe I to release the fragment containing the MCS, 
intron, and T7 promoter and generate compatible ends with the promoter fragment.  The 
vector backbone was also treated with Antarctic Phosphatase to remove the 5’ phosphates 
and prevent self-annealing.  Each component (vector backbone and promoter insert) was 
then purified by phenol/EtOH extraction to remove the restriction enzymes (Bgl II is not 
inactivated by heat).  Ligation of these components was performed by the Quick Ligation 
Kit (NEB) and the ligation product (pRL-mPGp) was transformed into OneShot Stbl3 
chemically competent cells (Invitrogen).  Plasmid DNA from transformed cells was 
isolated using a midi-prep kit (Qiagen, Germantown, MD).  
To correct for the error of removing the T7 promoter and intron by the cloning 
scheme described in the last paragraph, the scheme depicted in Figure C.4 was 
implemented in which the mPGp was excised from the pRL-mPGp vector and inserted 
into the pSE280 cloning vector to add additional restriction sites to the ends of the 
promoter and facilitate its transfer into the pRLnull vector at the appropriate site 
upstream of the T7 promoter and intron. 
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C.2.4 Transfection and Luciferase Expression Assay 
Enteroendocrine GLUTag L-cells, T84 enterocytes, and NIH-3T3 fibroblasts were 
transfected via FugeneHD using the manufacturer’s protocol at a ratio of 8 µl FugeneHD 
to 2 µg plasmid DNA.  Three days after transfection, the supernatant was removed and 
cell monolayers were lysed and assayed for luciferase activity by the Renilla Luciferase 
Assay System (Promega) according to manufacturer’s protocol. 
Figure C.4 Cloning scheme to correct the mPGp placement in the pRLnull vector. 
The mPGp was excised from the pRL-mPGp vector and inserted into the pSE280 
cloning vector to facilitate its transfer into the pRLnull vector upstream of the T7 

















C.3 Results and Discussion 
Promoter insertion was confirmed by size comparison of bands after gel 






Differences in expression level of the proglucagon promoter by various cell types 
was determined by normalizing the expression of the proglucagon promoter vector to 
expression from the promoterless vector (pRLnull, Figure C.6) or the CMV-containing 
vector (pRL-CMV, Figure C.7) to account for differences in transfection efficiencies 
among cell types. 
Figure C.5 Sequence of the cloned vector containing the proglucagon promoter.  
Underlined code matches with the target sequence identified in the materials and 
methods section.  The italicized code is the added restriction sites, and bold text 























































































































Figure C.7 Proglucagon promoter expression in various cell lines normalized to 
CMV vector expression.  Parallel cultures of GLUTag L-cells, T84 enterocytes, and 
NIH-3T3 fibroblasts were transfected with three different plasmids: one containing 
no promoter (Null), one containing the CMV promoter (CMV) and finally one 
containing the murine proglucagon promoter.  Luciferase expression from the 
proglucagon promoter in each of the cell types is expressed as a percentage of the 
CMV promoter N=3. 
Figure C.6 Proglucagon promoter expression in various cell lines normalized to null 
vector expression.  Parallel cultures of GLUTag L-cells, T84 enterocytes, and NIH-
3T3 fibroblasts were transfected with three different plasmids: one containing no 
promoter (Null), one containing the CMV promoter (CMV) and finally one 
containing the murine proglucagon promoter.  Luciferase expression from the 
proglucagon promoter in each of the cell types is expressed as a percentage of the 
Null promoter N=3. 
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GLUTag cells displayed the highest level of expression from the proglucagon 
promoter vector, 179.8 ± 93.1% normalized to null vector expression compared to just 
17.3 ± 4.3% for T84 and 40.7 ± 21.5% for NIH-3T3 cells (mean ± SD).  Though L-cell 
specific expression was observed, the level of luciferase expression exhibited by the 
proglucagon promoter vector was only 11.4 ± 5.6% the level obtained from the CMV 
vector in GLUTag cells.  Given however that the CMV promoter is one of the strongest 
known promoters, this comparison may not be entirely appropriate, and perhaps 11% of 
CMV-driven expression would be useful in certain studies.   
The sequence cloned in this chapter included ~420 bp of the upstream flanking 
region, this should have been ample enough to include all of the promoter elements 
described in the proglucagon promoter (Cordier-Bussat, Morel et al. 1995), though the 
glucagon upstream enhancer (GUE) region is located between -1253 and -2292 bp (Jin 
and Drucker 1995) and was not included.  It is possible that if a longer sequence had been 
cloned to include the GUE region, expression from the proglucagon promoter may have 
been improved.  When this experiment was performed by Jin and Drucker, however, 
relative luciferase expression, compared to Null vector expression, of the vector 
containing 2058 bp of the 5’ flanking sequence rose to only 290% compared to 200% 
from the vector containing only 476 bp of the 5’ flanking sequence (Jin and Drucker 
1995).  Thus, though the contribution of the GUE region may be important for tissue 
specific processing, most of the expression level is determined by the proximal 5’ 
flanking region. 
It is important to note that the cell lysates were collected following three days of 
regular culture without any attempt to stimulate expression, for example by up-regulating 
transcription via the cAMP-promoting agent, forskolin (Brubaker, Schloos et al. 1998), to 
stimulate transcription through the CRE site.  It would be interesting to see how 
expression levels change if the cells are stimulated prior to preparation of the lysates. 
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